Voluntary Oral Methamphetamine Reveals Susceptibilities to Spatial Memory Deficits, Decreased Dopamine Marker Expression and Increased Neuroinflammation in the Hippocampus of Male and Female Mice by Avila, Jorge A
How does access to this work benefit you? Let us know! 
More information about this work at: https://academicworks.cuny.edu/gc_etds/3511 
Discover additional works at: https://academicworks.cuny.edu 
This work is made publicly available by the City University of New York (CUNY). 
Contact: AcademicWorks@cuny.edu 
City University of New York (CUNY) 
CUNY Academic Works 
All Dissertations, Theses, and Capstone 
Projects Dissertations, Theses, and Capstone Projects 
9-2019 
Voluntary Oral Methamphetamine Reveals Susceptibilities to 
Spatial Memory Deficits, Decreased Dopamine Marker Expression 
and Increased Neuroinflammation in the Hippocampus of Male 
and Female Mice 
Jorge A. Avila 
The Graduate Center, City University of New York 
VOLUNTARY ORAL METHAMPHETAMINE REVEALS SUSCEPTIBILITIES TO 
SPATIAL MEMORY DEFICITS, DECREASED DOPAMINE MARKER EXPRESSION 
AND INCREASED NEUROINFLAMMATION IN THE HIPPOCAMPUS OF MALE 
AND FEMALE MICE 
 
by 
 
JORGE ANDRES AVILA 
 
 
 
 
 
 
 
 
 
 
A dissertation submitted to the Graduate Faculty in Psychology in partial fulfillment of the 
requirements for the degree of Doctor of Philosophy 
 
The City University of New York 
2019 
  ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2019 
 
JORGE ANDRES AVILA 
All Rights Reserved 
iii 
Voluntary Oral Methamphetamine reveals susceptibilities to spatial memory deficits, decreased 
dopamine marker expression and increased neuroinflammation in the hippocampus of male and 
female mice 
by 
Jorge Andres Avila 
This manuscript has been read and accepted for the Graduate Faculty in Psychology in 
satisfaction of the dissertation requirement for the degree of Doctor of Philosophy. 
Date DR. PETER A. SERRANO 
Hunter College, Chair of Examining Committee 
Date DR. RICHARD BODNAR 
Executive Officer 
      Supervisory Committee: 
Date DR. MARIA E. FIGUEIREDO-PEREIRA 
Hunter College Biological Sciences 
Date DR. THOMAS PREUSS 
Hunter College Psychology 
Date DR. WAYNE HARDING 
Hunter College Chemistry 
THE CITY UNIVERSITY OF NEW YORK 
ABSTRACT 
Voluntary Oral Methamphetamine reveals susceptibilities to spatial memory deficits, 
decreased dopamine marker expression and increased neuroinflammation in the 
hippocampus of male and female mice 
By 
Jorge Andres Avila 
Advisor: Peter A. Serrano 
Methamphetamine is an addictive illicit psychostimulant that produces lasting 
neurochemical and behavioral changes. The mechanisms underlying these deficits have been 
characterized in animal models using extremely high doses. Currently, better translational 
models are needed to understand the onset and progression of these deficits that more accurately 
reflect the gradual and voluntary dosing parameters as chosen by an abuser. To that end, a new 
model of methamphetamine administration, labeled Voluntary Oral Methamphetamine 
Administration (VOMA), offers a means to examine the progression of neurotoxicity, behavioral 
deficits, and the addiction process through a voluntary consumption framework.  
Female populations show consistent vulnerabilities to methamphetamine, including 
greater severity of abuse, and greater shifts in psychological health. Females also show increased 
neurochemical susceptibilities during abstinence from methamphetamine, exhibiting increased 
grey-matter loss compared to controls. The mechanisms underlying these female-specific 
susceptibilities to methamphetamine are unknown.  
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The overall GOAL of these studies was to establish a voluntary methamphetamine 
administration model in mice that recapitulates the cognitive and neurochemical deficits shown 
with previous models to further our understanding of the long-term susceptibilities of at-risk 
populations, including adolescent and female subjects. 
Rodents can exhibit drug-preference and drug-seeking behaviors, and methamphetamine 
challenges can reproduce the behavioral and neurochemical deficits that human addicts show. 
However, it is unclear if mice would voluntarily consume methamphetamine, and what effects 
this administration design would produce in this mice. Thus, the studies presented in this 
dissertation characterized the utility of the VOMA model to produce 1. naturalistic 
methamphetamine consumption 2. behavioral deficits and 3. neurochemical changes. This was 
done in an effort to understand the 4. mechanisms underlying adolescent- and female-specific 
vulnerabilities to the drug.  
To achieve our GOAL, we carried out three (3) specific aims: 
Specific Aim 1: Determine the utility of Voluntary Oral Methamphetamine 
Administration (VOMA) to produce behavioral and neurochemical deficits as seen in 
previous models [Chapter 2] 
In modeling MA abuse with rodents, researchers have developed paradigms that inject 
neurotoxic or binge doses in mice that are 10 times higher than the lower limits we have 
characterized in our models 1 (reviewed in2). Previous work in this line of research has found that 
two (2) 30mg/kg MA doses can acutely increase spatial working-memory performance but also 
increase spatial working-memory errors in the long-term. These effects were correlated to 
decreased DA and synaptic plasticity maker expression in the hippocampus 1. These prior studies 
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have contributed significantly to our understanding of the mechanisms underlying MA toxicity 2, 
but offered very little in understanding the voluntary nature of methamphetamine administration.  
In order to characterize the utility of VOMA in producing MA consumption that produced 
cognitive and neurochemical deficits, we combined a spatial cognition design with a drug 
administration design as follows:  mice were randomly assigned to either a water/control group or 
MA for 28 consecutive days. To carry out voluntary oral MA administration (VOMA) in mice, 
MA was mixed into a palatable sweetened oatmeal flake that mice were drawn to and ingested 
orally. Mice were allowed to consume MA throughout a 3-hour administration period, within 15 
min intervals. Following 28-days of VOMA, mice were sacrificed, and tissues were collected. 
We found that VOMA: 
(1) Decreased working-memory and reference-memory performance of male mice on the
radial arm maze. These behavioral deficits were observed after the 28-day drug
administration period over a 2-week abstinence period.
(2) Increased neurotoxicity in the hippocampus, as observed through lower dopamine
marker expression, increased neuroinflammation, and lower synaptic-plasticity marker
expression.
Overall, these results indicate that VOMA can produce the behavioral and the 
neurochemical deficits observed in previous animal models as well as in human methamphetamine 
addicts. Additionally, that the molecular deficits were observed in the hippocampus highlights the 
utility of the model to easily characterize correlative cognitive behaviors and the underlying 
molecular shifts.  
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Specific Aim 2: Characterize the role of abstinence in perpetuating 
methamphetamine-induced deficits using VOMA [Chapter 3] 
MA abuse can produce long-term cognitive impairments in abstinent individuals3-5 but 
other studies have shown that long periods of abstinence can improve the recovery of decision 
making-skills and emotional symptoms6. This may help individuals to avert relapse and yet, 
other reports indicate that relapse can occur after abstinence7, as a result of exposure to specific 
environmental cues8. The neurochemical pathways affected by abstinence from MA are also 
unclear. An understanding of the progression of behavioral and neurochemical changes produced 
by MA abuse and by abstinence would provide pharmacological targets to aid in recovery from 
addiction.  
In order to characterize the role of abstinence in producing MA-induced behavioral and 
molecular deficits, we used an acute VOMA design to do the following: put adolescent mice 
through cognitive assessments directly after 14 days of MA exposure and after a prolonged 
abstinence period. Tissue was collected directly after VOMA and after a 4-week abstinence period. 
We found that VOMA: 
(1) Produced a transient sensitization to MA as seen through behavior analyses in the drug-
context
(2) Produced an acute spatial working-memory deficit on the RAM directly after VOMA
We found that abstinence: 
(1) Did not produce long-term working-memory, reference learning, nor retention deficits
on the RAM
(2) Increased expression of neuroinflammatory markers in the hippocampus
(3) Modulated expression of monoamine proteins in the hippocampus
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Overall, these results indicate that abstinence from VOMA acutely affects behavioral 
performance that is ameliorated by abstinence. Further, abstinence produces neurochemical 
changes not observed directly following VOMA. This demonstrates that even acute MA exposure 
is sufficient to produce molecular changes in the brain despite not manifesting in behavior. This 
highlights the susceptibility of the adolescent brain to acute MA exposure and provides new 
avenues for pharmacological studies aimed at preventing MA-induced deficits.  
Specific Aim 3: Characterize the sex-differences in behavior and neurochemistry 
following escalating dose of methamphetamine using VOMA [Chapter 4] 
Previous work has shown that females exhibit susceptibilities to psychostimulant-addiction 
9-12. It has been reported that methamphetamine use in female populations  can be attributed to
factors including weight loss, desire for increased energy and work output, and decreased 
exhaustion 13-14. Data on drug-rehabilitation admissions show that young female participants are 
admitted at higher rates compared to males 15. One hypothesis for sex differences in 
psychostimulant addiction highlights estrogen’s facilitation of neuronal and behavioral 
development of drug addiction processes in the brain. 16-18. However, this idea remains untested. 
Additionally, previous work has shown that escalating doses of methamphetamine have 
intrinsic neuroprotective qualities that protect the brain and behavior from a chronic administration 
of the drug. The nature and source of this neuroprotection is unclear, but previous work has shown 
that this phenomenon occurs in binge injection models, 19-20, associated with decreases in 
methamphetamine binding to DAT and decreases in the resulting DA availability in the synapse. 
However, the underlying mechanisms that produce this change in DA sensitivity remain unknown. 
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To test how female subjects respond differentially to VOMA, we modified our 
administration design to include a 10-day escalation period, wherein mice would receive gradually 
escalating doses of and access to methamphetamine prior to receiving the maximum access and 
dose. We hypothesized that that this administration design would produce the maximal voluntary 
consumption over a shorter (18-day) period and produce the maximal behavioral and molecular 
deficits that could be observed.  
We found that Escalation-VOMA: 
(1) Decreased working-memory of female mice on the radial arm maze shortly after the
conclusion of VOMA. This deficit was not observed in male mice that were placed into
VOMA.
(2) Discrete shifts in neuroprotective signaling (D1, ERα and Akt/GSK3β pathway) in the
hippocampus and nucleus accumbens of female mice after a 2-week abstinence period.
Male mice that underwent VOMA did not exhibit any molecular changes.
Overall, this study showed that through VOMA, and with the aid of an escalating-dose 
design, we are able to observe sex-differences in the behavioral and neurochemical changes that 
methamphetamine can produce. Interestingly, we also observed a previously reported 
neuroprotective effect of escalating doses in male subjects, but not in females. Our molecular 
investigations will provide future direction in basic research and clinical endeavors to target 
methamphetamine addiction.  
Conclusion: The novel VOMA design has provided a more naturalistic approach to 
investigating the behavioral and molecular deficits produce by methamphetamine and abstinence 
during adolescence. With this model, we have successfully characterized longer-term 
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susceptibilities in mice than previous studies have shown. Furthermore, it has provided new 
insights into the sex-differences surrounding meth-abuse, including the role of neuroprotective 
pathway signaling as markers for susceptibilities/resilience to methamphetamine abuse. 
x
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CHAPTER 1: INTRODUCTION 
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1.1 Methamphetamine addiction: The negative consequences on behavior and cognition 
Methamphetamine (MA) abuse has an approximate $23.4 billion annual cost to society 21. Of this 
total, 71% can be attributed to intangible costs, including psychological stress and deficits. 
Studies on MA’s effects on cognitive and psychological functions have increased in the last 10 
years 22, with conflicting clinical studies showing both cognitive enhancements and cognitive 
deficits after acute exposure to MA. Conversely, clinical studies on chronic MA exposure 
indicate long-lasting and progressive cognitive decline in these MA abusers 23-24 Furthermore, 
the addictive and neurotoxic nature of the drug produces long-term cognitive impairments in 
abstinent individuals 4, 22-23. Thus, the time course of MA abuse and abstinence may play a major 
role in the progression of cognitive dysfunction. Chronic MA users develop cognitive deficits in 
sustained attention, episodic memory, information processing, and impulse control 25-28. Finally, 
hallucinations and cognitive impairment are clinical symptoms of MA psychosis in patients who 
show a sensitization to MA 29. Thus, research should seek to characterize the milieu of effects 
that MA can have on cognition, distinguishing between cognitive effects of acute vs. chronic MA 
exposure, as well as the specific cognitive capacities that are affected. Methamphetamine (MA) 
abuse is a costly and detrimental health risk in the U.S. and abroad. In the U.S., the number of 
individuals who reported abusing MA in 2012 was approximately 1.2 million people (4.7 percent 
of the population) 30. Amphetamine-type stimulants (ATS) now rank second only to cannabis as 
the most common illicit drugs used worldwide, representing approximately 34 million users 31. 
North America continues to be a significant market for ATS, particularly amphetamine and 
methamphetamine 32. Based on these statistics, it becomes increasingly important that we 
understand the risk factors associated with MA addiction, and develop new animal models to 
better address treatment outcomes for addicts. It is well known that MA abusers show a long-
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lasting reduction in dopamine terminals and transporters, both of which increase the risk for 
Parkinson’s Disease 33-34. Chronic MA abuse also results in neurodegeneration of frontal cortex, 
midbrain regions and hippocampus, which are all associated with memory deficits 35. 
Additionally, an increase in markers of neuroinflammation, including activated microglia was 
reported in MA abusers 36. Several animal studies have recapitulated many of these 
neurochemical and behavioral characteristics associated with MA abuse [reviewed in 2; briefly 
summarized in ]. Many animal studies show that neurotoxic or binge-dosing regiments of MA 
produce rapid increases in microglia 37 and glial fibrillary acidic protein (GFAP) levels within 
the striatum and hippocampus  38-40 shortly after administration. 
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Table 1: Molecular changes characterized in animal models of MA abuse. An overview of 
neurotoxic, dopaminergic and glutamatergic changes in the striatum and hippocampus of rodents 
highlighting the MA administration methods, the molecular markers used, and the timing of 
tissue collection. 
  
Neurotoxicity Effect Markers/Method 
MA Administration 
Protocol 
Tissue 
Collection 
Brain 
region 
Study 
Increased pyknotic nuclei BRDU/cell counts I.P. 30mg/kg 12 weeks Striatum 41 
Increased apoptosis 
TUNNEL 
staining/cell counts 
I.P. 10mg/kg, 20mg/kg, 
30mg/kg, 40 mg/kg 
24 hrs Striatum 42 
Decreased cell density 
Cresyl Violet 
stain/cell counts 
I.P. 30mg/kg 24 hrs Striatum 42 
Increased astrocytosis 
GFAP IHC/Cell 
counts 
10mg/kg x4 1 wk Striatum 43 
No increases in 
neurodegeneration 
Fluorojade C IHC 
6d Escalating doses (10-
25mg/kg) + 30mg/kg on d7 
24 hrs Striatum 44 
      
Dopaminergic dysregulation Markers/Method 
MA Administration 
Protocol 
Tissue 
Collection 
Brain 
region 
Study 
Decreased DARPP-32 neurons 
DARPP-32 IHC/cell 
counts 
I.P. 30mg/kg 24 hrs Striatum 42 
Decreased D1 receptor levels D1/Western Blot I.P. 30mg/kg x2 6 wks Hippocampus 1 
Increased DAT levels DAT/Western Blot I.P. 30mg/kg x2 6 wks 
Hippocampus 
+ Striatum 
1 
Decreased DAT levels DAT/Western Blot 10mg/kg x4 1 wk Striatum 43 
Decreased TH levels 
TH IHC/Optical 
density 
10mg/kg x4 1 wk Striatum 43 
      
Glutamatergic 
dysregulation 
Markers/Method 
MA Administration 
Protocol 
Tissue 
Collection 
Brain 
region 
Study 
Increased NMDA receptor levels 
GluN2B/Western 
Blot 
I.P. 30mg/kg x2 6 wks Hippocampus 1 
Decreased AMPA and NMDA 
receptor levels 
GluA2 + 
GluN2B/Western 
Blot 
I.P. 30mg/kg x2 6 wks Striatum 1 
Increased AMPA receptor levels GluA2/Western Blot 
6d Escalating doses (10-
25mg/kg) + 30mg/kg on d7 
24 hrs Striatum 44 
Increased NMDA receptor levels 
GluN2B/Western 
Blot 
6d Escalating doses (10-
25mg/kg) + 30mg/kg on d7 
24 hrs Striatum 44 
Decreased AMPA receptor levels GluA2/Western Blot 30mg/kg 24 hrs Hippocampus 38 
Decreased NMDA receptor levels GluN1/Western Blot 
6d Escalating doses (10-
25mg/kg) + 30mg/kg on d7 
24 hrs Hippocampus 38 
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1.2 The Neurocircuitry of Methamphetamine addiction: The vulnerability of the 
Hippocampus 
MA is known to directly affect the monoamine neurotransmitter systems 45. Clinical MA abusers 
show deceased density of dopamine transporters (DAT) in the striatum and frontal cortex 33, 46-47, 
two regions associated with reward processing and drug addiction 48-50. However, chronic MA 
abuse also results in neurodegeneration of frontal cortex, midbrain regions and hippocampus and 
is associated with memory deficits 35. Additionally, the ventral hippocampus-ventral striatum 
circuit is known to participate in stimulant-induced expression of drug addiction behaviors 50, 
suggesting that stimulant abuse could alter hippocampal-dependent behaviors through changes in 
hippocampal synaptic plasticity. In fact, a recent study has found that neurotoxic doses of MA can 
alter DA and glutamate marker levels in the hippocampus, affecting hippocampal-dependent 
behaviors 1. Additional evidence of hippocampal vulnerabilities to MA come from proteomic 
studies that found the drug to increase major apoptotic, inflammatory, and neurodegenerative 
pathway activity in this region 51. Activation of inflammatory and degenerative pathways in the 
brain are hypothesized to underlie the progression and development of neurodegenerative diseases 
like Alzheimer’s and Parkinson’s disease 52. Thus, serving a variety of roles within drug abuse and 
exhibiting many important molecular vulnerabilities, the hippocampus is emerging as a pivotal 
region in the study of MA abuse and addiction. 
 
1.3 The acute and lasting effects of Methamphetamine abuse on the brain 
MA can produce a variety of neurobiological effects once it has been consumed. The primary 
mechanism of action of MA in the brain is to act on dopamine (DA) and serotonin (5-HT) 
synapses. MA spills neurotransmitter into the cytosol via interactions with VMAT2 (synaptic 
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vesicle channel pump), followed by reversing DAT function and decreasing SERT activity (DA 
and 5-HT reuptake transporters (respectively)), leading to increased neurotransmitter release and 
post-synaptic receptor activation 45. These processes underlie the euphoria produced by MA. 
However, these processes become dangerous very quickly. Once DA has been displaced to the 
cytoplasm, it rapidly auto-oxidizes to form reactive oxygen species (ROS) that include 
superoxide radicals, DA quinones 45. Increased MA-dependent ROS formation has been linked to 
decreased tryptophan hydroxylase (TPH) (5-HT rate-limiting enzyme) activity in the 
hippocampus through oxidation of TPH as early as 1 hour after MA treatment 53 and linked to 
increased tyrosine hydroxylase (TH) (DA rate-limiting enzyme) activity and DA synthesis that 
contribute to MA-induced neurotoxicity and  damage to DA terminals. 54. Further evidence of 
ROS-induced damage from MA comes from 55 who showed that administration of neurotoxic 
doses of MA to rats caused DA oxidation to DA-quinones that bind to cysteinyl residues on 
proteins, increasing protein cysteinyl-DA levels in the striatum. Protein oxidation in the brain 
can result in various signaling, homeostatic and even behavioral deficits, as revealed by studies 
of protein oxidation using amphetamine derivative, ecstasy (MDMA), and ethanol 56. These 
mechanisms can cause DA terminal degeneration leading to reductions in dopamine availability, 
which can increase the risk of Parkinson’s Disease and its associated symptoms 33-34. Studies 
have also elucidated the effects of MA on the glutamate system, reviewed in 57-58. MA 
synergistically increases DA terminal depletions through glutamate activity 59, but also can 
increase glutamate release via reactive-nitrogen-species activation 60, and can cause glutamate 
excitotoxicity and calpain-dependent proteolysis via AMPA receptor activation 61 in the striatum. 
More recent studies have shown that neurotoxic doses of MA can cause decreases in AMPA 
receptor and synaptic scaffolding and trafficking markers, PSD-95 and PKMζ, in the 
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hippocampus 1 which could underlie the spatial learning and memory deficits revealed in the 
same studies. These MA-induced effects on the DA and glutamate systems can have far-reaching 
effects on cognitive functioning and require detailed investigations in behavioral models of MA 
abuse (Fig 1).  
The effects of MA on the brain and behavior depend on how similar its chemical structure is to 
DA, which allows the drug to enter DA terminals through DAT reuptake 45 or through lipid 
membranes due to the high lipophilic nature of the compound 62-63. Once inside the axon, MA 
can sequester VMAT2, also likely due to the similarity to DA, and through pH changes in the 
synaptic vesicle microenvironment 64 spills DA from synaptic vesicles into the cytoplasm 45. 
Through interactions with DAT, MA can induce reverse transport of cytosolic DA into the 
synaptic cleft 45. This increased availability of DA at the synapse is what allows for increased 
DA release, and once the MA-dependent increases in DA release occur in the nucleus accumbens 
and prefrontal cortices (brain regions that compute reward), the individual feels euphoria. This 
mechanism is understood to be the underlying end of MA abuse by addicts.  
 
Once DA has been displaced to the cytoplasm by MA and VMAT2-depedent mechanisms, it 
rapidly auto-oxidizes to form reactive oxygen species (ROS) that include superoxide radicals, 
hydroxyl radicals, hydrogen peroxide and DA quinones 45. Increased MA-dependent ROS 
formation has been linked to decreased tryptophan hydroxylase (TPH) (5-HT rate-limiting 
enzyme) activity in the hippocampus through oxidation of thiol groups of TPH as early as 1 hour 
after MA treatment 53. Further evidence of ROS-induced damage from MA comes from 55 who 
showed that administration of neurotoxic doses of MA to rats caused DA oxidation to DA 
quinones that bind to cysteinyl residues on proteins, which lead to an increase in protein 
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cysteinyl-DA levels in the striatum. These increases in oxidation of DA occurred only under 
conditions resulting in neurotoxicity, suggesting that the oxidation of DA may play a major role 
MA-induced damage to DA terminals. It is well known that MA abusers show a long-lasting 
reduction in dopamine terminals and transporters both of which increase the risk of Parkinson’s 
Disease 33-34.   
 
There is evidence that links the 5-HT transporter (SERT) to MA-induced damage of 5-HT 
terminals. A number of SERT inhibitors, including fluoxetine, have been shown to block MA-
induced reductions in TPH activity and prevent 5-HT depletion in the striatum, hippocampus and 
cortex 45 suggesting a role for SERT in MA-induced 5-HT terminal degeneration. Clinical 
Positron emission tomography (PET) studies have shown decreased levels of serotonin 
transporter (SERT) in the orbitofrontal and occipital cortices in individuals who were currently 
abstinent from MA 65-66. These individuals also showed increased aggression, highlighting how 
MA abuse and addiction can alter emotional and psychiatric health. 
 
MA neurotoxicity is also driven by excitotoxic damage following glutamate release and 
activation of glutamate receptors 67. MA-induced glutamate release in the striatum is thought to 
be initiated by DA D1 receptor-dependent stimulation of striatonigral GABAergic pathway that 
causes increases in GABA release in the substantia nigra pars reticulata, inhibition of 
nigrothalamic GABAergic outflow via activation of GABAA receptors, and followed by 
disinhibition of thalamocortical afferents with resulting increases in striatal glutamate release 68.  
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Microglia are the resident immune cells in the brain that protect against injury and long-term 
damage 69. In the healthy brain, microglial cells exist in a quiescent state and they monitor the 
neuronal environment for any signs of injury and assist in housekeeping duties as it becomes 
necessary 69-70. However, in response to trauma, injury, or disease, microglial cells increase in 
size, migrate to the site of the injury, and undergo a series of signaling and phagocytic events 
that enable them to respond adequately to begin the process of repair 69-70. While microglial 
activation is essential for immune responses and restoration of normal neuronal function, the 
persistent or unceasing activation of microglial cells can result in neurotoxic consequences. 
Indeed, multiple lines of evidence have suggested that activated microglia release a variety of 
cytokines, reactive oxygen and nitrogen species and PGs that are known to cause neuronal 
damage during responses to injury 70-71 and, therefore, might be involved in neurodegeneration 
through pro-inflammatory processes. Importantly, prostaglandin-J2 (PGJ2), the most neurotoxic 
of all PGs, is a direct product of pro-inflammatory activity via COX-2 dependent mechanisms, 
and can feed-back onto COX-2 pathways to upregulate pro-inflammatory activity 72. A goal of 
this proposal is to determine the levels of PGJ2 in VOMA mice, in order to delineate the state of 
inflammatory processes in the brain due to MA abuse. In fact, an increase in markers of 
neuroinflammation, including activated microglia has been reported in MA abusers 36. Another 
report shows that the pro-inflammatory marker COX-2 increases in the striatum 73 occur as a 
result of MA use and is an obligatory factor in the neurotoxicity induced by the drug. 
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Figure 1. Model of Methamphetamine-induced effects on the brain and cognition. Neuro-
glial activation potentiates a neuroinflammatory response that can perpetually affect synaptic 
plasticity and in turn cognition.  
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1.4 The role of escalating exposure on Methamphetamine-induced effects 
Because binge or bolus neurotoxic MA administration are not thought to model the typical 
pattern of human MA use, several groups of investigators focused their attention on using 
escalating MA dosing to investigate its effects on the brain. For example, one study administered 
MA on an escalating dose regimen, where injections were given 3x/day for 13 days starting at 
0.1 mg/kg bw (s.c.) and increased by 0.1 mg/kg with every injection, so that on the 13th day, the 
animals received 3.9 mg/kg 74.This was done with the idea that some addicts would gradually 
escalate their doses and frequency of intake45. Assessing the neurochemical deficits associated 
with MA in this dosing paradigm potential protective effects that occur as a result of repetitive 
dosing spread out across days. These reports reveal that differing doses across consecutive days 
may provide some neuroprotection and/or delay the long-term damage 19-20.  
 
1.5 Susceptibility in adolescent and female populations to Methamphetamine abuse 
A significant body of literature has shown that select populations, females 9-12 and adolescents 75-
76, exhibit susceptibilities to psychostimulant-addiction. It has been reported that MA use in female 
populations  can be attributed to factors including weight loss, desire for increased energy and 
work output, and decreased exhaustion 13-14. Data on adolescent trends of abuse are sparse, but 
available studies suggest complex psycho-social dynamics at play in the progression of MA abuse 
in these populations 77. Furthermore, data on MA treatment admissions show that younger age 
groups are admitted at a higher rates and that in these younger groups, females are admitted at 
higher rates compared to males 15. Mechanistic studies on the effects of MA in these populations 
indicate neurobiological resilience to neurotoxic regimens of MA 78-79, although the underlying 
mechanisms of this resilience in adolescents remain unclear 80. One hypothesis for sex differences 
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in MA abuse highlights estrogen’s facilitation of neuronal and behavioral development of drug 
addiction processes. 16-18. Models to explain the susceptibility of adolescent psychostimulant abuse 
are focusing on developmental trajectories of cortico-limbic circuits and the impact of 
environmental stress on psychosocial-dependent behavioral dynamics 81-82. However, not much is 
known about the long-term trajectories of hippocampal behaviors and molecular profiles stemming 
from MA abuse in these populations.  
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2.1  Abstract 
Methamphetamine (MA) is an addictive drug with neurotoxic effects on the brain producing 
cognitive impairment and increasing the risk for neurodegenerative disease. Research has 
focused largely on examining the neurochemical and behavioral deficits induced by injecting 
relatively high doses of MA [30 mg/kg of body weight (bw)] identifying the upper limits of MA-
induced neurotoxicity. Accordingly, we have developed an appetitive mouse model of voluntary 
oral MA administration (VOMA) based on the consumption of a palatable sweetened oatmeal 
mash containing a known amount of MA. This VOMA model is useful for determining the lower 
limits necessary to produce neurotoxicity in the short-term and long-term as it progresses over 
time. We show that mice consumed on average 1.743 mg/kg bw/hour during 3 hours, and an 
average of 5.23 mg/kg bw/day over 28 consecutive days on a VOMA schedule. Since this 
consumption rate is much lower than the neurotoxic doses typically injected, we assessed the 
effects of long-term chronic VOMA on both spatial memory performance and on the levels of 
neurotoxicity in the hippocampus. Following 28 days of VOMA, mice exhibited a significant 
deficit in short-term spatial working memory and spatial reference learning on the radial 8-arm 
maze (RAM) compared to controls. This was accompanied by a significant decrease in memory 
markers protein kinase Mzeta (PKMζ), calcium impermeable AMPA receptor subunit GluA2, 
and the post-synaptic density 95 (PSD-95) protein in the hippocampus. Compared to controls, 
the VOMA paradigm also induced decreases in hippocampal levels of dopamine transporter 
(DAT) and tyrosine hydroxylase (TH), as well as increases in dopamine 1 receptor (D1R), glial 
fibrillary acidic protein (GFAP) and cyclooxygenase-2 (COX-2), with a decrease in 
prostaglandins E2 (PGE2) and D2 (PGD2). These results demonstrate that chronic VOMA 
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reaching 146 mg/kg bw/28d induces significant hippocampal neurotoxicity. Future studies will 
evaluate the progression of this neurotoxic state.  
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2.2  Introduction 
 
Methamphetamine (MA) abuse is a costly and detrimental health risk in the U.S. and abroad. In 
the U.S., the number of individuals who reported abusing MA in 2012 was approximately 1.2 
million people (4.7 percent of the population) 30. Amphetamine-type stimulants (ATS) now rank 
second only to cannabis as the most common illicit drugs used worldwide, representing 
approximately 34 million users 31. North America continues to be a significant market for ATS, 
particularly amphetamine and methamphetamine 32. Based on these statistics, it becomes 
increasingly important that we understand the risk factors associated with MA addiction and 
develop new animal models to better address treatment outcomes for addicts. It is well known 
that MA abusers show a long-lasting reduction in dopamine terminals and transporters, both of 
which increase the risk for Parkinson’s Disease 33-34. Chronic MA abuse also results in 
neurodegeneration of frontal cortex, midbrain regions and hippocampus, which are all associated 
with memory deficits 35. Additionally, an increase in markers of neuroinflammation, including 
activated microglia was reported in MA abusers 36. Several animal studies have recapitulated 
many of these neurochemical and behavioral characteristics associated with MA abuse [reviewed 
in 2]. Many animal studies show that neurotoxic or binge-dosing regiments of MA produce rapid 
increases in microglia 37 and glial fibrillary acidic protein (GFAP) levels within the striatum and 
hippocampus  38-40 shortly after administration. 
 
While there are many MA paradigms for rodents currently used, what is needed is a model that 
capitalizes on the voluntary MA consumption without the need for conditioning to administer the 
drug or surgery that can restrict the types of behavioral assessments used. Here we provide data 
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on a voluntary oral methamphetamine administration (VOMA) model useful for determining the 
progressive nature of voluntary abuse-associated neurotoxicity in a rodent model. Our goal was 
to assess the effectiveness of this VOMA model in producing hippocampal-dependent memory 
and learning deficits, as well as MA-associated neurochemical changes. To evaluate cognitive 
behavior we used the radial arm maze (RAM), which is a hippocampal-dependent task 83-84 used 
to assess both long-term reference and short-term working memories 1.  
 
Following behavioral assessments, we quantified changes in (1) dopamine-related markers 
involving tyrosine hydroxylase (TH), dopamine transporter (DAT), and the Dopamine 1 receptor 
(D1R); (2) glutamate receptor alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA) 
GluA2 subunit; (3) atypical protein kinase C iota/lambda (PKCι/λ), protein kinase Mzeta 
(PKMζ) and the post-synaptic density 95 (PSD-95) protein; and (4) markers of inflammation 
involving astrogliosis measured by GFAP, cycloxygenase-2 (COX-2), and prostaglandins (PG) 
E2, D2 and J2. We focused on these molecular markers since MA selectively damages DA 
terminals and produces excitotoxicity effects involving AMPA receptors 85-86 in addition to 
elevated levels of inflammation 38. Astrogliosis is associated with MA neurotoxicity and several 
other toxic insults in the brain 87. Finally, as a synaptic plasticity and memory marker, we 
focused on the atypical kinase PKMζ that is important for spatial learning and long-term memory 
88-89, and which is increased concomitantly with improved memory 90 across several memory 
paradigms [reviewed in 91].  
 
Our results show that 28d on VOMA produces significant deficits in hippocampal-dependent 
short-term working and long-term reference learning on the RAM. These behavioral deficits 
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were associated with decreases in PKMζ, GluA2 and PSD-95. VOMA also produced decreases 
in DAT and TH, with a concomitant increase in D1R levels. Both GFAP and COX-2 increased, 
with decreases in PGE2 and PGD2. Thus, these results highlight the accumulating negative 
effects of chronic VOMA in addition to its usefulness in characterizing the progression of the 
MA-induced neurotoxicity.  
 
2.3  Material and Methods  
 
2.3.1 Mice 
 
Male C57BL/6 mice from Taconic Farms (Germantown, NY) were purchased at 8 weeks of age. 
Mice were randomly assigned to 2 treatment conditions: MA (n = 5) and Control (n = 5). We 
have used similar sample sizes to evaluate behavioral performance and protein expression as 
previously reported 1, 90, 92. Mice were housed individually to control for social effects of group 
housing 93 that could affect the voluntary consumption of methamphetamine in our model. Mice 
were kept on a 12/12 h light/dark cycle at the Hunter College animal facility for one week prior 
to beginning any behavioral assessments with food and water ad libitum prior to behavioral 
shaping. All housing conditions conform to the Hunter College guidelines outlined by the 
Institutional Animal Care and Use Committee (IACUC). 
 
2.3.2 Methamphetamine Treatment 
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We used a new voluntary oral methamphetamine administration (VOMA) model over 28 
consecutive days (experimental days 5-32). A sweetened oatmeal flake (Maypo, Homestat Farm, 
Dublin, OH) was moistened with 8-10 μl of either MA (2.5 mg/ml) or water. This produces a 
palatable sweetened oatmeal flake that contains 1mg MA/kg of body weight (bw) per serving 
(adjusted to mice ranging in weight between 20-25 g). During MA administration, all mice were 
transferred to individual mouse cages that were lined with absorbent paper. Each cage was 
designated to a specific mouse throughout the experiment to ensure context specificity. Cages 
were wiped clean and lined with fresh paper after each use. All mice remained in their paper-
lined cage for 30 min prior to treatment. During a 3 hour (hr) period, from 13:00 h to 16:00 h, 
mice were presented with individual MA or water moistened oatmeal flakes. A new presentation 
was delivered in a clean petri dish every 15 min. For each mouse, the number of consumed 
flakes during the 3 hr period was noted. Directly after VOMA, all mice were fed 4g of mouse 
chow daily at 18:00 h. This feeding schedule ensured that mice would be willing to consume 
oatmeal flakes during the VOMA treatment time-window, for 28 consecutive days. This feeding 
schedule also circumvented the significant circadian effects reported on VOMA administration 
94, without disrupting weight gain throughout the duration of the experiment. 
 
2.3.3 Radial 8-arm Maze Shaping 
 
The radial 8-arm maze (RAM) was used to assess both working memory and spatial learning 
performance. The maze consists of a center platform (15.24 cm diameter) with 8 equivalently 
sized arms radiating outward. Each arm is 38 cm in length, 6.35 cm wide and has a submerged 
food cup (2.0 cm diameter) at the end of each arm. Maypo was mixed in water to make a wet 
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mash used as a food reward (0.02 g portions), as previously described for mice 1 and rats 88. Prior 
to working memory assessments, all animals were shaped on the RAM during days 1-2 of the 
study. Mice were food restricted to 85% of free feeding weight before being placed on the RAM 
for 10 min to acclimate to the maze and room cues. 1 hr later, all mice were given a second trial 
with sweetened oatmeal in the food cups. After 1 day of shaping (2 trials per day), mice were 
eating the food rewards and finding all 8 baits within a 15 min maximum latency.  
  
2.3.4 Working Memory Assessment  
 
The working memory assessment (WMA) occurred during experimental day 37. Mice were 
tested for 1 day (3 consecutive trials). Each trial started with all food cups baited. To begin each 
trial, mice were confined for 30 s to the center platform with a plastic cylinder. Between trials 
mice were confined to the center platform while the arms were re-baited and the maze cleaned. 
The sequence of arms entered to retrieve the food rewards was recorded. Mice were allowed to 
collect baits from up to 3 sequential arms in any direction around the radial arm maze. Under 
rare instances when a mouse adopted a chaining strategy by entering consecutive arms in one 
direction around the maze, the 4th sequential arm was blocked to disrupt this non-spatial strategy 
1. Errors were recorded as re-entries into arms where the food reward had already been collected. 
Working memory was assessed by a % correct score for each trial, which was calculated by the 
number of total arm entries required to collect all 8 food rewards divided by 8 (the total number 
of rewards collected). All mice remained on the maze until all 8 baits were collected. Maximum 
latency for each trial was set at 15 min. 
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2.3.5 Spatial Learning/Cognitive Flexibility Assessment 
 
During experimental days 40-49, all mice were trained on a reference and working memory 
version of the RAM as previously reported 1. This paradigm had 4 baited and 4 un-baited arms in 
a pattern that was specific to each animal and remained constant throughout the experiment. 
Mice were given 6 consecutive trials per day for 10 days (60 trials total). Between trials mice 
were confined to the center platform while the arms were re-baited and the maze cleaned. The 
sequence of arm entries was recorded. A reference memory error reflected an entry into an arm 
that was never baited, while working memory errors reflected re-entries into an arm where the 
bait had already been collected. Mice were only allowed to enter up to 3 sequential arms to 
prevent the non-hippocampal dependent chaining strategy. This version of the RAM required 
mice to learn room cues associated with the baited and un-baited arm sequence. The training 
room and room cues were identical to that used for the WMA. 24 hrs after the last RAM trial, all 
mice were given one reminder trial on the maze 1 hr prior to tissue retrieval. Hippocampi from 
each mouse were removed, snap frozen and stored at −80oC until processed further.   
 
2.3.6 Preparation of Tissue Fractions 
 
Hippocampi were micro dissected and fractionated into cytosolic and synaptic fractions as 
previously reported 1. Briefly, tissues were thawed and homogenized in a TEE (Tris 50mM; 
EDTA 1mM; EGTA 1mM) buffer containing a Sigma Fast, protease inhibitor cocktail (Sigma 
Aldrich) diluted to contain AEBSF (2 mM), Phosphoramidon (1 mM), Bestatin (130 mM), E-64 
(14 mM), Leupeptin (1 mM), Aprotinin (0.2 mM), and PepstatinA (10 mM). Tissues were 
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homogenized in 200 μl of the TEE-homogenization buffer using 20 pumps with a motorized 
pestle. Homogenates were transferred to Eppendorf tubes and centrifuged at 3000 x g (5 min at 
4° C), to remove un-homogenized tissue. The resulting supernatant was centrifuged at 100,000 g 
for 30 min. After ultracentrifugation, the supernatant was collected and stored as the cytosolic 
fraction. The remaining pellet was re-suspended in 100 μl of homogenizing TEE buffer 
containing 0.001% Triton X-100, incubated on ice for 1 hr and then centrifuged at 100,000 g for 
1 hr at 4°C. The resulting supernatant was stored at the plasma-membrane fraction. The resulting 
pellet was re-suspended in 50 μl of TEE buffer and stored as the synaptic fraction 95. The Pierce 
bicinchoninic acid assay (BCA; Thermo Scientific, Rockford, IL, USA) was used to determine 
protein concentration for each sample. Samples were reduced with 4x Laemmli sample buffer 
equivalent to 25% of the total volume of the sample and then boiled and stored frozen at -80°C.   
 
2.3.7 Immunoblots  
 
Samples (20 μg) were loaded on to a Tris/Glycine 4–20% mini gel to resolve GAPDH (37 kDa), 
α-Tubulin (55 kDa), PKMζ (55 kDa), PKCι/λ (68 kDa), GluA2 (102 kDa), PSD-95 (95 kDa), 
COX-2 (72 kDa), GFAP (53 kDa), TH (60 kDa), D1 (49 kDa) and DAT (69 kDa). Every gel 
contained 4 lanes loaded with the same control sample designated as all brain sample (ABS). 
ABS was used to standardize protein signals between gels. Gels were transferred to 
nitrocellulose membranes in the IBlot® Dry Blotting System (Life Technologies; Carlsbad, CA, 
USA) for 7 min. Nitrocellulose membranes were then incubated in blocking solution containing 
5% sucrose in Tris Buffered Saline with Tween-20 (TBST; 0.1% Tween-20 in TBS) for 30 min 
at room temperature. Samples were incubated overnight with the following primary antibodies: 
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GluA2 (1:2000; Chemicon, Temecula, CA, USA), PKMζ/ PKCι/λ (1:2000; Santa Cruz 
Biotechnology, Santa Cruz, CA, USA), GAPDH (1:2000; Abcam Inc., Cambridge, MA, USA), 
PSD-95 (1:1000; Cell Signaling Technology, Danvers, MA, USA), COX-2 (1:1000; Santa Cruz 
Biotechnology, Santa Cruz, CA, USA), GFAP (1:5000; Abcam Inc., Cambridge, MA, USA), TH 
(1:2000; ab152, Millipore, Billerica, MA, USA), D1 (1:2000; Abcam Inc., Cambridge, MA, 
USA), DAT (1:1000; EMD Millipore, Temecula, CA, USA) and α-Tubulin (1:2000; 
Calbiochem, San Diego, CA, USA). Membranes were washed in TBST for 20 min and probed 
with Horseradish Peroxidase (HRP) conjugated secondary antibodies: Goat Anti-Mouse IgG (H 
+ L)-HRP Conjugate #1706516 (BioRad); Goat Anti-Rabbit IgG (H + L)-HRP Conjugate 
#1706515 (BioRad); Rabbit Anti-Goat IgG H&L (HRP) (ab6741-Abcam). Membranes were 
incubated with Enhanced Chemiluminescence (ECL) substrate and exposed on CL-X Posure 
Film (Thermo Scientific; Rockford, IL, USA). Films were scanned, and then densitometry was 
performed with NIH ImageJ 96. 
 
2.3.8 Preparation of Samples for Prostaglandin Quantification 
 
For prostaglandin quantification, pre-weighed hippocampal tissues were homogenized in 0.9 ml 
of phosphate buffered saline using a BeadBug microtube homogenizer. Following 
homogenization, a 10-mg wet weight equivalent of homogenate was removed and diluted to a 
final volume of 10 mg per 0.9 ml before being further diluted 1:1 with 1% formic acid. 
Deuterated internal standards were added (identified in italics in the table below) to the diluted 
homogenate and loaded on a 2 ml Biotage SLE+ cartridge. After a 5 min incubation, the 
cartridges were eluted twice with 6 ml of t-butlymethylether. The eluent was spiked with 20 μl of 
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a trap solution consisting of 10% glycerol in methanol with 0.01mg/ml butylated 
hydroxytoluene. The samples were dried for 45 minutes in a speed vacuum at 35°C, the walls of 
the tubes were washed with 1 ml of hexane and re-dried until a small aqueous residue remained. 
The residue was dissolved in 50 μl of 80:20 water:acetonitrile with 0.1 mg/ml butylated 
hydroxytoluene and spin filtered with a 0.22μm Millipore Ultrafree® filter. Samples were 
transferred to vials and 30 μl of sample were analyzed. Prostaglandin standard curves were 
spiked into PBS and prepared identically to the samples. Area ratios were plotted and unknowns 
determined using the slopes. 
 
2.3.9 LC-MS/MS for Prostaglandin Quantification 
 
Samples were analyzed using a 5500 Q-TRAP hybrid/triple quadrupole linear ion trap mass 
spectrometer (Applied Biosystems, Carlsbad, CA) with electrospray ionization (ESI) in negative 
mode. The mass spectrometer was interfaced to a Shimadzu (Columbia, MD) SIL-20AC XR 
auto-sampler followed by 2 LC-20AD XR LC pumps. The scheduled MRM transitions were 
monitored within a 1.5 min time-window (supplemental Table 1). Optimal instrument parameters 
were determined by direct infusion of each analyte. The gradient mobile phase was delivered at a 
flow rate of 0.5 ml/min, and consisted of two solvents, 0.05% acetic acid in water and 
acetonitrile. The analytes were resolved on a Betabasic-C18 (100x2 mm, 3 µm) column at 40°C 
using the Shimadzu column oven. Data was acquired using Analyst 1.5.1 and analyzed using 
Multiquant 3.0.1(AB Sciex, Ontario, Canada).   
 
2.3.10 Statistics 
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For behavioral analyses, a repeated measure Two-Way ANOVA was used (Prism GraphPad 7.0a 
Statistical Package, La Jolla, California). Post-hoc analyses used Bonferroni-corrected t-tests. 
Western blot and PG mass-spec analyses between MA and control treatments used independent 
t-tests. To characterize the generalizability of our results and support the magnitude of effects in 
our studies independent of sample size, effect sizes are reported. Effect sizes were calculated as 
generalized eta squared (2G) for behavioral data and Hedge’s unbiased g (g) for post-hoc 
analyses and molecular data, using IBM SPSS Statistics for Mac (Armonk, NY: IBM Corp.), and 
Microsoft Excel as previously described 97. For our studies, benchmark coefficient thresholds 
for large effects 97 were taken into account and inflated in order to restrict significance. The 
thresholds for large effect sizes in our studies were as follows: when 2G was 0.2 or higher, and 
when g was 0.8 or higher. Effect sizes below these criteria were deemed moderate. 
  
2.4  Results 
 
2.4.1 Shaping and Methamphetamine administration 
 
The study began with shaping animals for a total of 2 days. After 4 total days of acclimation, 
subjects were randomly assigned to either a water/control group or MA for 28 consecutive days 
(days 5-32). The WMA was performed on day 37 after 5 days of forced abstinence from MA. 
This was followed by 10 days of cognitive flexibility assessment on the reference/working 
memory version of the RAM (days 40-49). Tissue was collected on day 50 (Figure 2A). Over the 
28d period mice consumed an average of 5.23 mg/kg of MA/day. Figure 2B reflects the average 
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weekly consumption of MA. Control mice ate every presentation of water-Maypo. Figure 2C 
shows the average weekly weights for both conditions. A two-way ANOVA shows no significant 
difference between the groups [F(1,32) = 1.55, p > 0.05; 2G = 0.023, non-significant effect size] 
indicating that the Maypo consumption, with or without MA, was not influenced by differences 
in body weight between conditions.   
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Figure 2. Timeline for the 50d study, Average Methamphetamine (MA) Consumption and 
Body Weights. (A) Days 1-2: behavioral shaping on RAM. Days 5-32: VOMA for 28d. Day 37: 
working memory assessment. Days 40-49: cognitive flexibility assessment (spatial learning).  
Day 50:  RAM test and tissue harvest. (B) The total amount of MA consumed over the 28 day 
VOMA period, grouped into 4-week averages for Control and Methamphetamine (Meth) groups. 
(C) Mice were weighed during the consumption period of VOMA. No significant differences 
were found between the two groups when analyzed by two-way ANOVA [F(1,32) = 1.55, p > 
0.05; 2G = 0.023, non-significant effect size] 
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2.4.2 Radial- Arm-Maze Working and Reference Memory Assessments  
 
Figure 3A shows the % correct scores in two separate analyses to illustrate the differences in 
number of errors committed during a trial. Collecting the first 4 baits, when the working memory 
load is low, shows a much higher % correct score compared to when the working memory load is 
high, collecting baits 5-8. An overall 2-way ANOVA reflecting treatment condition (MA or 
saline) and baits (1-4 or 5-8) shows a significant effect of bait [F (1,8) = 50.67, p < 0.001; 2G 
=0.76, significant effect size]. The Bonferonni post-hoc analysis shows significant within-group 
differences in both control (Bonferonni corrected t-test=3.14, p < 0.05; g= 1.57) and VOMA 
(Bonferonni corrected t-test=6.93, p<0.001; g= 4.85) mice when comparing group performances 
between collecting baits 1-4 and baits 5-8.  Between groups, there were no significant differences 
between treatments for baits 1-4 (Bonferonni corrected t-test = 0.39, p > 0.05; g= 0.23) In 
contrast, VOMA produced a significant increase in working memory errors while collecting baits 
5-8 compared to controls (Bonferroni corrected t- test= 3.41, p < 0.01; g= 1.92).  Figure 3B 
shows the latency to complete the working memory trials. There were no significant differences 
between treatment conditions for latency to complete working memory trials (Figure 3B).  
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Figure 3: VOMA impairs spatial working memory.  (A) Two-way Repeated ANOVA showed 
an overall effect of bait group (*** p<0.001). Post hoc analyses reveal that both control and MA 
mice performed significantly worse to retrieve baits 5-8 compared to baits 1-4 (# indicates 
different from control bait 1-4, p<0.05; ! indicates different from MA bait 1-4, p<0.001). Baits 5-
8 reveal a significant difference between groups (^ indicates different from control in same 
condition p < 0.01). (B) There was no significant difference in latency to complete the trial 
between the groups. 
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Figure 4 shows the behavioral analyses for RAM acquisition across 10 training days (experiment 
days 40-49 shown on graphs). An overall 2-way ANOVA for % correct scores (Figure 4A) 
shows a significant interaction effect of treatment on training days [F(9,72) =5.12, p < 0.01; 2G = 
0.29] and time [F(9,72) =33.38 , p < 0.01; ; 2G = 0.73]. Post hoc tests show significant differences 
between treatment conditions for training day 8 (Bonferroni corrected t-test = 3.45, p < 0.01; g= 
1.97) and training day 9 (Bonferroni corrected t-test = 4.28, p < 0.01; g= 2.44). To determine 
whether there are significant differences in asymptotic performance level between groups, we 
assessed % correct scores during training days 6-10 (experiment days 45-49). This analysis 
shows an overall effect of drug treatment [F(1,8) = 10.99, p < 0.05; 2G = 0.40], reflecting 
differences in the level of peak performance. As predicted with asymptotic performance, there 
was no significant effect of training days. Consistent with % correct score analyses, reference 
memory errors shown in Figure 4B reflect an overall significant interaction effect of treatment on 
training days [F(9,72) = 3.75, p < 0.01; 2G =0.25], and a significant effect of training days [F (9,72) 
=25.00, p< 0.01; 2G = 0.69]. During asymptotic performance (training days 6-10 experiment 
days 45-49), reference memory errors show an overall significant effect of treatment [F(1,8) = 
13.8, p< 0.01; 2G = 0.33]. Analysis of working memory errors (Figure 4C) shows an overall 
significant effect on training [F(9,72) = 5.25, p < 0.01; 2G = 0.35], but no significant effect 
between treatment conditions. During asymptotic performance (training days 6-10, experiment 
days 45-49), there was a significant effect of treatment [F(1, 8) = 5.513, p<0.05; 2G = 0.20] for 
working memory errors. Together the data in Figure 4A-C demonstrate that MA is significantly 
impairing the level of peak performance across multiple analyses on this spatial learning task. 
Analysis of latency to complete the training trials shows a significant interaction effect of 
treatment on training days [F(9,72)=4.92, p <0.01; 2G = 0.23] and an overall significant decrease 
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over training days [F(9,72) = 22.01, p < 0.01; 2G =0.57]. Post-hoc tests show a significant 
difference between treatment conditions on training day 1 (Bonferroni corrected t-test= 3.31, 
p<0.05; g= 1.89).   
 
  
  32 
 
 
Figure 4. VOMA impairs spatial learning.  All statistical analyses involved two-way ANOVA 
across 10 consecutive training days (experiment days 40-49 shown on graphs) and treatment 
conditions. Differences between treatment conditions during asymptotic performance (training 
days 6-10, experiment days 45-49) were analyzed separately. (A) % Correct shows a significant 
effect of training days (^ p < 0.0001) and treatment conditions (# p < 0.0001). Bonferroni-
corrected post hoc analyses revealed significant differences between treatment conditions on 
training days 8 and 9, (experiment days 47-48) (** p < 0.01; *** p<0.001). During asymptotic 
performance (training days 6-10) there is a significant treatment effect (! p<0.05).  (B) Reference 
memory errors show a significant effect on training days (^ p < 0.01), a significant interaction (# 
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p < 0.01), and a significant treatment effect during asymptotic performance (training days 6-10, ! 
p<0.01). (C) Working memory errors show a significant effect of training days (^ p < 0.01), 
without a significant difference between treatment conditions except during asymptotic 
performance (training days 6-10, ! p<.05). (D) Latency to complete the trials show a significant 
effect of training days (^ p < 0.01), and a significant interaction between treatment conditions (# 
p < 0.01). Bonferroni post-hoc tests show a significant difference between treatment conditions 
on training day 1 (p<0.05). 
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2.4.3 Hippocampal Dopaminergic Marker Expression 
 
Western blot analyses for dopaminergic markers showed a significant decrease in cytosolic TH 
(t7= 2.67, p<0.05, g= 1.59; Figure 5A). In the synaptic fraction, there was a significant increase 
in D1R expression (t8= 3.16, p<0.01, g= 1.81, Figure 5B) and a decrease in synaptic DAT 
expression (t7= 2.16, p<0.05, g= 1.29, Figure 5C).  
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Figure 5. Chronic VOMA affects dopaminergic marker expression. Compared to controls, 
VOMA decreases cytosolic TH (*p<0.05; A). In the synaptic fraction, D1R significantly 
increased (**p<0.01; B) and DAT significantly decreased (*p<0.05; C) compared to controls. 
Representative blots show control (left band) and MA (right band) treatments. See 
supplementary figures for original images of blots.  
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2.4.4 Hippocampal Inflammatory Marker Expression 
 
Inflammatory markers showed a significant increase of synaptic COX-2 (t8= 1.93, p<0.05, 
g=1.09, Figure 6A) and cytosolic COX-2 (t7= 2.03, p<0.05, g= 1.211, Figure 6B). Cytosolic 
GFAP was also significantly elevated compared to controls (t7= 3.86, p<0.01, g=-2.30, Figure 
6C). GFAP and COX-2 increases suggest a raise in proinflammatory activity in the 
hippocampus. MA-induced excitotoxicity can mediate increases of GFAP to allow for astrocyte 
activation in response to MA-induced damage 98. COX-2 is an inducible inflammatory activator 
that can signal other pathways, including prostaglandin synthesis, which can be protective or 
toxic to neurons 99. Figure 6D-F shows analyses of PGE2, D2 and J2 in picograms per milligram 
of wet weight of tissue, indicating that PGD2 levels in control mice are at least 10-fold higher 
than PGE2 and PGJ2. Both PGE2 and PGD2 significantly decrease (33% and 40% respectively) 
with VOMA compared to controls (t8 = 3.95, p < 0.05; g= 2.26, Figure 6D. t8=3.73, p< 0.01; g= 
2.13, Figure 6E.). PGJ2, which is a PGD2 metabolite, did not change significantly between 
treatment conditions (Figure 6F).  
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Figure 6. Chronic VOMA increases neuroinflammation marker expression. In the synaptic 
(A) and cytosolic (B) fractions COX-2 levels significantly increased compared to controls 
(*p<0.05). (C) Cytosolic GFAP increased compared to controls (**p<0.01). See supplementary 
figures for original images of blots. (D,E). PGE2 and PGD2 significantly decreased with VOMA 
compared to controls (*p< 0.05; picograms/milligram). (F). PGJ2 expression did not change 
significantly between treatment conditions. Representative blots show control (left band) and 
MA (right band) treatments.  
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2.4.5 Hippocampal Synaptic Plasticity Marker Expression 
 
Compared to controls, VOMA produced a significant decline in glutamatergic and synaptic 
plasticity markers including GluA2 (t6= 8.53, p<0.01, g= 5.24, Figure 7A), synaptic PSD-95 (t8= 
3.38, p<0.01, g= 1.93, Figure 7B) and cytosolic PKMζ (t8=2.55, *p<0.05, g= 1.46, Figure 7C). 
Cytosolic PKCι/λ expression was not altered by VOMA treatment (Figure 7D).   
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Figure 7. Chronic VOMA decreases memory associated marker expression. (A) In the 
synaptic fraction, VOMA decreased GluA2 (**p<0.01) and PSD-95 compared to controls 
(**p<0.01; B). (C) In the cytosolic fraction, VOMA decreased PKMζ compared to controls 
(*p<0.05). (D) VOMA did not significantly affect cytosolic PKCι/λ expression. Representative 
blots show control (left band) and MA (right band) treatments. See supplementary figures for 
original images of blots. 
  
  40 
2.5  Discussion 
 
2.5.1 VOMA as a model for studying MA addiction 
 
VOMA is a new model for assessing both the chronic and acute effects of MA. MA mixed in a 
palatable sweetened oatmeal mash provides a paradigm that does not require surgery or 
conditioning. This model permits the animal unrestricted movement that allows the experimenter 
to test various behavioral learning paradigms. Our results demonstrate that chronic voluntary 
consumption of MA results in significant spatial learning and memory deficits together with 
significant changes in markers reflective of MA neurotoxicity. One of the main challenges in 
MA research is designing an experiment that models aspects of human MA addiction. We find 
that this VOMA model is useful for characterizing aspects of addiction, as mice are able to titer 
the amount of drug administered, as reflected by a consistent level of MA consumed over several 
weeks. Our results indicate that the C57BL/6 mice will voluntary consume about 1.743 mg/kg 
bw/hr during a 3 hr MA administration period. These data suggest that if 5mg/kg bw MA was 
delivered as a bolus dose to a mouse of this strain, even such a seemingly low dose is 
considerably higher than would be consumed voluntarily. Whether there is a difference between 
an injection of 5 mg/kg bw compared to voluntarily consuming this amount over a 3 hr period 
remains to be determined. Other MA models have used appetitive paradigms 94 or drinking 
paradigms 100 that also demonstrate the short-term behavioral and neurochemical changes 
associated with small doses of voluntary MA consumption. In our current study, we examine the 
behavioral and neurochemical effects of chronic voluntary MA as a way to more accurately 
model human MA addiction.  
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Throughout 28 days of VOMA, consumption rates increase over the first 2 weeks and stabilize 
during the last 2 weeks. Previous self-administration models may only reveal a trend to increase 
consumption due to the brief (2 weeks or less) administration window. It is unclear how other 
self-administration models would compare to VOMA across longer periods administration (4 
weeks or more). Moreover, it is important to consider how oral administration via a sweetened 
medium might affect VOMA. Control mice in our study consumed every presentation of water-
Maypo (12 baits/day over 28 days), revealing a preference for sweetened food by this mouse 
line. However, mice that consumed water-Maypo laced with MA consumed less than half of the 
baits presented to them each day on average (see Results). This reveals that although a sugar 
preference could motivate consumption of the MA-baits, mice rapidly adapt a strategy to 
consume only as much MA-Maypo as they prefer. Mice on VOMA could still develop a 
preference to MA as a result of the sweetened medium, but more work is needed to determine 
this. Future studies should examine how the drug’s medium affects consumption rates across 
long periods of MA access.  
 
The use of an oral administration design is validated by previous work indicating that the mean 
half-elimination life of oral MA is not significantly different from that of the intravenous route, 
and that peak plasma concentration is delayed via the oral route by 3 hrs in humans, compared to 
other routes 101-102. This suggests that VOMA can model the delayed effects of MA on the brain, 
and very adequately reveal the prolonged neurotoxic effects of the drug. Additionally, previous 
work has revealed that although the injection route may be preferred by a subset of highly-
addicted individuals, non-injection routes make up a high percentage of MA use in the United 
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States 103. Nonetheless, our study models oral MA administration, a route not likely preferred by 
MA-addicted humans. Non-injection MA administration might be preferred by individuals who 
have not yet developed an addiction. In order to fully understand the distinct populations that 
abuse MA, more research is needed to clarify the onset and progression of this addiction in 
humans as it relates to administration routes. Future VOMA studies should examine the 
progression and relapse of MA consumption in VOMA in order to accurately characterize the 
addictive phenotype produced by our model.  
 
2.5.2 MA-induces deficits in both spatial working and reference memory performance 
 
Our results show that total MA consumption of 146.4 mg/kg bw/28 consecutive days result in a 
significant spatial working memory performance deficit. Our previous study reports working 
memory deficits following neurotoxic doses of MA (30 mg/kg bw delivered once per week for 2 
weeks; 60mg/kg bw total). These working memory deficits developed over a 4 week abstinence 
period 1. The working memory deficit observed in our current study may have developed much 
earlier based on the levels of MA consumed. However, reports by others suggest that lower 
doses of MA delivered chronically may have less harmful or delayed cognitive effects, compared 
to bolus or neurotoxic doses 38, 104. The latter studies are consistent with the protective effects 
observed when escalating doses of MA are delivered over days that show reduced cognitive and 
neurochemical deficits, compared to neurotoxic effects and the resulting cognitive deficits that 
result from a bolus dose 105-108. Rapid deficits in working memory performance identified 24 hrs 
following a neurotoxic dose of MA were previously reported 38. However, without repeated 
assessments over time, it is difficult to determine whether the working memory deficits are long 
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lasting or are reflective of the short-interval between MA treatment and working memory testing. 
It is possible that shortly after MA administration, mice are low on seeking novelty, an effect that 
is rectified weeks after MA treatment as demonstrated in rat performance on the spontaneous 
alternation task 109.  
 
Following the working memory assessment, mice were tested for cognitive flexibility on the 
RAM. For this assessment, both working and reference memory errors were scored. The MA 
treated mice exhibited a lower asymptotic performance level for % correct scores and an increase 
in the number of reference and working memory errors compared to mice given control 
treatment. This is consistent with several other studies reporting spatial memory deficits 
following a short abstinence period 110-112. Others have shown that chronic use of MA can 
actually stave off MA-induced deficits, which can then be initiated following long-periods of 
abstinence. In this case, cognitive deficits were observed only following long-term abstinence (1-
4 weeks) 1, 104, 113-114. The degree to which VOMA produces neuroprotection and/or can delay the 
neurotoxic effects of MA remains to be determined.  
 
2.5.3 Chronic VOMA decreases TH and DAT while increasing D1R levels 
 
Our previous studies revealed that acute neurotoxic doses of MA (2x 30 mg/kg) followed by 6 
weeks of forced abstinence produce long-lasting decreases in dopamine marker expression in the 
hippocampus 1. In our current study, we found that VOMA for 28d also produced significant 
decreases in these markers in the hippocampus. Previous work has shown that within days of 
injecting neurotoxic doses of MA, the striatum exhibits a comparable decrease in DA levels 115-
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120. MA-induced reductions of TH and DAT in the striatum may indicate degeneration of DA 
axonal terminals 121-124. This explanation is supported by increased reactive astrogliosis 
associated with MA treatment 122, 125-126. We hypothesize that decreased DAT and TH together 
with an increase in astrogliosis reflects a degeneration of DA terminals within the hippocampus. 
Whether our VOMA paradigm produces similar effects in the striatum remains to be determined. 
 
VOMA also induced a significant increase in D1R expression. This receptor is known to mediate 
some of the MA-driven neurotoxic effects in the striatum 127 and PFC 128. Selective D1R 
antagonists delivered prior to injections of binge doses of MA produce neuroprotective effects 
against the MA-induced decreases in DA, TH and DAT 118. Moreover, increases in MA-induced 
extracellular DA causes acute increases in striatal glutamate as a result of D1R mediated 
disinhibition of corticostriatal glutamate release 129. Together these findings suggest that 
increased D1R expression is detrimental and/or exacerbates the neurotoxic damage from MA. In 
contrast, it has been suggested that D1R activation is a neuroprotective response. Dopamine 
suppresses glutamatergic hippocampal and entorhinal neurotransmission by activation of the 
D1R 130. Additionally, D1R activation can reduce NMDA receptor mediated Ca2+ currents in 
hippocampal neurons, thus decreasing excitotoxicity 131. The D1R also plays a role in reducing 
calcium currents in striatal neurons 127, and in producing inhibition on N-type voltage-gated 
calcium channels 132. Therefore, it is possible that alterations in other receptor levels dictate 
whether increased D1R-levels are beneficial or detrimental. Future studies will evaluate the 
changes in NMDA and mGluA receptor subunits, which could add to understanding the 
consequences of these neurochemical changes. For example, antagonism of NMDA, AMPA or 
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metabotropic (mGluR5) receptors can block MA-induced toxicity in the striatum 133-135 or 
hippocampus 136. 
 
2.5.4 Neuroinflammatory marker levels increase in the hippocampus following chronic VOMA 
 
We show that compared to controls, GFAP and COX-2 protein levels are elevated in the 
hippocampus after 28d of VOMA. We propose that these changes in inflammatory markers 
reflect a neurodegenerative response to MA. COX catalyzes the conversion of arachidonic acid 
to prostaglandins (PG) and thromboxanes. COX-1 is constitutively expressed, whereas COX-2 is 
induced upon stimulation by various proinflammatory agents (endotoxins, cytotoxins) 99, 137. 
Elevated levels of COX-2 in the hippocampus increase the extracellular concentration of 
glutamate, exacerbating glutamate-associated excitotoxicity 138-141. Our results are consistent 
with what is observed following neurotoxic doses of MA 142.  Conversely, COX-2 KO mice are 
resistant to MA-dependent dopamine depletion in the striatum that results from high doses 143, 
suggesting that COX-2 up-regulation exacerbates the neurotoxic effects of MA 144-145. Other 
reports show temporary GFAP increases in the hippocampus 24h after neurotoxic doses of MA, 
which return to basal levels by 7d post injection 39, 142. These data suggest that the rapid increases 
in GFAP induced by a neurotoxic dose of MA may reflect activation of a neuroregenerative 
response, as this marker is expressed during neurogenesis in the subgranular zone of the dentate 
gyrus 146. Based on these findings, it is possible that the accumulating (low doses) of MA during 
VOMA prolong the short-term increase in GFAP that has been observed following neurotoxic 
doses. Future studies should characterize the time course for the onset and progression of GFAP 
expression in the hippocampus after VOMA.  
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Following a regimen of neurotoxic MA administration (4× 10 mg/kg, 2 h apart, i.p.), mice 
exhibit cytotoxic brain edema driven by increases in hippocampal and striatal aquaporin-4 
channels on astrocytes 147. Increased GFAP expression in the hippocampus following VOMA 
suggests that after chronic MA abuse, the hippocampus is vulnerable to breakdown of the blood-
brain barrier resulting in cytotoxic edema. Astrocytes are one part of the complex neurovascular 
niche and aquaporins play a pivotal role in regulating water and cerebro-spinal fluid (CSF) flow 
into and out of the neuronal space 148-149. It is unclear how and when this dysregulation in 
aquaporin-mediated shifts in water/CSF emerges and is resolved after chronic MA abuse. Future 
studies should examine the role that aquaporin-mediated cytotoxic edema plays in VOMA-
induced neural and cognitive deficits.  
 
PGE2 and PGD2 levels decrease following VOMA. PGD2 is the most abundant of the PGs in 
the brain followed by PGE2, and both PGs induce secretion of nerve growth factor and brain-
derived neurotropic factor 150. In addition, both PGD2 and PGE2 were found to have 
neuroprotective effects in the CNS 151-153. These studies suggest that decreased levels of PGD2 
and PGE2, together with increased expression of COX-2 could mediate a neurotoxic response to 
VOMA. It is possible that the decrease in PGE2 reflects an increase in the 15-
hydroxyprostaglandin dehydrogenase (15-PGDH), a key enzyme in the metabolism of PGE2. An 
ALS mouse model shows that 15-PGDH increases throughout the progression of the disease 
specifically in GFAP positive astrocytes, while PGE2 only increased at the end stage of the 
disease 154. No other studies have measured PGs in the hippocampus following MA. One study 
examined binge doses of MA on PGE2 in the striatum showing no changes in PGE2 levels up to 
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48 hrs following MA 143. Further work is needed to delineate how these different MA models 
affect PGs across various brain regions.  
 
PGJ2 is a product of spontaneous dehydration of PGD2, which is the most abundant 
prostaglandin in the brain 155 and the one that changes the most under pathological conditions156. 
PGJ2 is a highly neurotoxic prostaglandin 157, as it impairs both the ubiquitin-proteasome 
pathway 158-159 and mitochondrial function 160. This PG also up-regulates COX-2 161, most likely 
leading to a positive feedback loop between itself and COX-2 99. In supplementary studies, we 
have observed that PGJ2 levels increase following 6 weeks of abstinence after acute neurotoxic 
doses of MA (2x 30 mg/kg; supplementary Figure 1) and also increases following 4 weeks of 
abstinence after a 2 week VOMA period (25 mg/kg total MA consumed over 14d; supplementary 
Figure 2). However, mice given 28d of VOMA did not exhibit increases in PGJ2 (Figure 6F). 
These data suggest that abstinence may be playing a role in the increased expression of PGJ2. 
This finding is consistent with previous studies indicating that abstinence from MA can 
exacerbate memory deficits 1, 114.  
 
Our results suggest that the duration of abstinence and of MA-administration could play 
opposing roles in promoting or suppressing PGJ2 levels in the hippocampus. We hypothesize 
that a long period of abstinence from MA promotes PGJ2 expression, but that a longer period of 
MA administration mitigates it through increased dopamine release. This hypothesis is consistent 
with the understanding that dopamine is anti-inflammatory by inhibiting the activation of NOD-
like receptor containing Pyrin domain-3 (NLRP3) inflammasome by D1R activation 162. 
Additional studies have shown that low doses of MA, which increase dopamine release, are 
  48 
neuroprotective following oxygen-glucose deprivation 163. However, it remains to be determined 
how abstinence from MA contributes to increases in PGJ2.  
 
2.5.5 MA decreases synaptic memory markers 
 
Our results show that the levels of PKMζ and AMPA receptor subunit GluA2 decrease following 
VOMA. PKMζ is important for both late-phase LTP 164 and long-term memory maintenance 
across various learning paradigms 88, 91, 165-166. It is also important to note that increased GluA2 
synaptic expression is important for spatial memory 90, 167, as is the trafficking of AMPA 
receptors by PKMζ 168-169. These studies are consistent with the decline in PKMζ and GluA2 
levels following VOMA. We also assessed the protein levels of PKCι/λ, another atypical kinase 
known to support spatial memory in the conditional-PKMζ KO mouse 170, suggesting that 
PKCι/λ is active when PKMζ is compromised.  PKCι/λ expression was not significantly altered 
following VOMA, suggesting that deficits in PKMζ may not reflect neurotoxic damage, but 
rather reflect poor learning.  
 
GluA2 is one of the four AMPA receptor subunits impermeable to Ca2+ and is the dominant 
heteromeric conformation 171-172. Reduced GluA2 levels were shown to increase neurotoxicity in 
amyotrophic lateral sclerosis motor neurons 173-174. We hypothesize that decreased GluA2 and 
PKMζ mediate spatial learning impairment as well as the elevated neurotoxic effects of MA. 
This is consistent with chronic MA treatment. In contrast, studies by others examining acute 
doses of neurotoxic MA report increased levels of GluA2 shortly after treatment 38, suggesting 
that elevated hippocampal GluA2 levels may be contributing to a neuroprotective response by 
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MA. However, after several weeks of abstinence, hippocampal GluA2 levels return to baseline 1. 
Together these results suggest that early after MA, hippocampal GluA2 increases as a 
neuroprotective mechanism, while following chronic MA a decline in hippocampal GluA2 could 
exacerbate MA neurotoxicity. These results are also consistent with our behavioral data, 
indicating that GluA2 decline in the hippocampus could underlie the spatial memory deficits 
found in VOMA mice. 
 
Our results also show a significant decrease in PSD-95 protein levels. PSD-95 is primarily 
located in the neuronal spine head and its density reflects synaptic efficacy 175. Moreover, 
increases in PSD-95 spine density are associated with improved memory performance 176-178. 
These findings are consistent with the poor memory performance and reduced hippocampal 
PSD-95 level in the MA treated mice. PSD-95 levels also increase in the forebrain following 
MA-induced place preference 179, suggesting PSD-95 involvement in memory rather than a 
secondary effect of MA-induced toxicity.  
 
2.6  Conclusions 
 
Our data demonstrate that chronic VOMA leads to significant deficits in spatial learning and 
short-term working memory, which is consistent with reports by others. Additionally, our results 
show that low doses of MA consumed over a 3 hr period can produce significant neurotoxic 
changes in the hippocampus, reproducing the neurochemical effects observed in studies using 
bolus or neurotoxic doses of MA. Chronic VOMA also leads to significant decreases in TH and 
DAT and an increase in D1R expression as seen with neurotoxic and binge doses of MA. These 
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neurochemical changes are accompanied by increases in both COX-2 and GFAP that were 
previously reported. In concert with the decline in PGE2 and PGD2 levels, these data may reflect 
extensive neurotoxic damage attributed to MA. Finally, decreases in synaptic markers relevant to 
spatial long-term memory involving both GluA2 and PKMζ are consistent with neurotoxicity-
induced deficits in working memory and spatial learning. The time course for the onset and 
progression of these various neurochemical changes in the VOMA model remains to be 
determined. These data are consistent with what is observed in MA addicts showing low levels 
of dopamine, DAT and TH associated with cognitive impairment 34, 180. Together these studies 
support the significance of this VOMA mouse model in identifying risk factors and exploring 
potential remediation therapies against MA addiction. 
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2.7.Supplementary Figures 
 
 
Figure 8. Supplemental Figure 1. Prostaglandin levels in hippocampus after 14d VOMA 
followed by 4wks of abstinence. (A) PGE2 and (B) PGD2 levels did not differ between 
treatment conditions. (C) PGJ2 levels significantly increased in MA condition compared to 
controls (t9=2.23; *p=0.026, g=1.34) 
 
 
 
Figure 9. Supplemental Figure 2.  Prostaglandin J2 levels increase in mice hippocampi 6 
weeks after two bolus doses of MA (2x 30 mg/kg). (A) PGE2 and (B) PGD2 levels did not 
differ between treatment conditions. (C) PGJ2 levels significantly increased in MA 6-week 
condition compared to MA 3-day condition (t5=3.24; *p=0.023, g= 2.09) 
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Table 2: MRM transitions for prostanoids and deuterated internal standards for PG Mass 
Spectrometry. The scheduled MRM transition values monitored within a 1.5 min window. 
 
 
ID Q1 Q3 RT DP EP CE CXP 
PGD2 351.1 233 6.20 -60 -10 -18 -19 
d9 PGD2 360.1 280.2 6.15 -55 -10 -26 -19 
PGE2 351.0 189.1 5.9 -85 -10 -26 -5 
PGJ2 333 233.2 7.59 -55 -10 -16 -9 
d9 PGE2 360.2 280.2 5.9 -75 -10 -28 -11 
6 keto PGF1α 369.1 163.1 4.2 -120 -10 -38 -3 
d4 6 keto PGF1α 373.1 167.2 4.2 -120 -10 -38 -11 
IsoP VI 353.2 115.0 5.5 -55 -10 -30 -5 
8,12 IsoP VI 353.1 115.0 6.6 -85 -10 -30 -7 
d4 IsoP VI 357.2 115.0 5.5 -125 -10 -30 -9 
IsoP III 353.2 193.0 5.2 -105 -10 -36 -3 
IsoP IV 353.0 126.9 5.0 -75 -10 -32 -11 
d4-IsoP III 357.2 197.0 5.2 -125 -10 -36 -7 
PGF2α 353.1 193 5.7 -55 -10 -34 -31 
d4 PGF2α 357.1 197 5.7 -55 -10 -34 -31 
TXB2 369.1 169.1 5.2 -75 -10 -28 -5 
11 dehydroTXB 367.1 305.2 6.0 -65 -10 -24 -11 
d4 TXB2 373.1 173.1 5.2 -60 -10 -30 -5 
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3.1 Abstract 
Methamphetamine (MA) is a neurotoxic drug of abuse. It can produce neurodegenerative 
processes in the brain that impair behavioral and cognitive functions. The mechanisms that 
underlie MA-induced neurodegeneration are well characterized, but less is known about how 
MA induces behavioral and cognitive deficits. Furthermore, little is known about the progression 
of behavioral deficits immediately after MA abuse and during abstinence. To address these gaps 
in knowledge, our lab has developed a voluntary oral administration model of MA (VOMA) 
using mice. Male C57Bl6 mice were put through VOMA for 14 days followed by a prolonged 
period of abstinence. During VOMA, mice were allowed to voluntarily consume up to 16mg/kg 
of MA each day. During and after VOMA, mice were put through a battery of cognitive and 
behavioral assessments to test drug sensitization, spatial memory capacities, and long-term 
retention. Our results show that VOMA produces subsets of MA consumers in mice, accurately 
modeling voluntary MA abuse in humans. Our behavioral data reveals that VOMA produced an 
acute sensitization to MA, and an acute working spatial memory deficit directly after VOMA. 
However, VOMA did not produce a long-term spatial learning or retention deficit during 
abstinence. Hippocampal tissue analyses of mice from different timepoints reveal that abstinence 
significantly increases neuroinflammation, and significantly contributes to modulations in 
synaptic dopamine transporter and 5-5-hydroxytryptamine receptor 2A (5HT2a) expression. Our 
study characterizes the progression of behavioral changes that follow MA administration, 
revealing that mice do not exhibit cognitive deficits during abstinence. Neurochemical analyses 
reveal that abstinence contributes to major changes in hippocampal neuroinflammation and 
monoamine protein expression. These findings provide new insight into the complex behavioral 
resilience and neurochemical susceptibility exhibited by MA subjects during abstinence. 
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3.2 Introduction 
Methamphetamine (MA) is a highly neurotoxic and addictive psychostimulant. Studies show that 
MA is increasing in popularity and abuse in the United States181. MA exposure during critical 
developmental periods can impair cognition in rodents182, as well as humans183, and can 
significantly affect neurochemistry184. Chronic MA users develop hallucinations29 as well as 
cognitive deficits in attention, memory, information processing, and impulse control25-28. MA 
abuse can also trigger negative emotional states such as depression during drug withdrawal and 
abstinence185. These deficits may be attributed to neurodegeneration of the frontal cortex, 
midbrain and hippocampus35. Additionally, increased MA exposure correlates with greater 
locomotion in mice186-187 and can also affect various unconscious physiological behaviors such 
as food intake188. In order to determine the progression of behavioral changes following MA 
intake, the current study used a new model of methamphetamine administration labeled 
Voluntary Oral Methamphetamine Administration (VOMA)189. Previous MA administration 
animal models have used binge and neurotoxic dosing via injections45. These models do not 
accurately represent the human model since people are not likely to take binge or neurotoxic 
doses in a short periods of time. Instead, humans may opt to spread out similar MA doses over a 
longer span of time. The VOMA model allows mice to titer the amount of MA they consume in a 
day and over many weeks. For this particular study, we exposed mice to VOMA for 2 weeks and 
a long abstinence period of up to 7 weeks prior to tissue collection or behavioral assessments.  
 
The trajectories in behavioral and neurochemical changes during abstinence from MA remain 
unclear. MA abuse can produce long-term cognitive impairments in abstinent individuals3-5. It 
has also been shown that long periods of abstinence from MA can improve the recovery of 
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decision making-skills and emotional symptoms6 which may help individuals to avert relapse. 
Yet, other reports indicate that relapse can still occur after prolonged abstinence7, as a result of 
exposure to specific environmental cues8. The underlying neurochemical pathways that result in 
relapse during abstinence remain unclear. Previous work has implicated glutamatergic signaling 
in the nucleus accumbens as pivotal in addiction models190, and recent evidence has also linked 
hippocampal neurogenesis to context-dependent MA memory during abstinence191-192. A 
thorough understanding of the neurochemical mechanisms underlying MA relapse during 
abstinence would provide pharmacological targets to assure successful recovery from addiction. 
Since the abstinence and relapse are also vital to studying addiction193, our experiments focused 
on tissue analyses from two (2) timepoints following VOMA, to characterize the progression of 
neurochemical changes in this animal model of drug abuse.  
 
As a result of MA-induced neurotoxicity, neuroinflammatory pathways are activated in the brain 
involving astrocytes and pro-inflammatory enzymes57, 145, 194. The contribution of abstinence to 
neuroinflammatory pathway activation and/or silencing is unclear. Parallel neurochemical 
changes following MA abuse include those that also occur in psychiatric disorders, including 
changes to dopamine and serotonin signaling195-196. Previous literature has revealed a link 
between serotonin signaling, via the 5HT2a receptor, with cognition197, hallucinogenic drugs198-
199 and psychiatric disorders200. Additionally, MA abusers also show decreased density of 
dopamine transporters (DAT) in the striatum and frontal cortex33, 46-47, as markers for 
degeneration of DA innervations in the brain121-124. It is unclear when DAT function is 
compromised following MA exposure and under what circumstances this function is restored 
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during abstinence. Our study characterizes changes in these markers following VOMA and after 
abstinence.  
 
3.3 Methods 
3.3.1 Animals 
All experimental conditions, housing, and drug administration procedures were reviewed and 
approved by the Institutional Animal Care and Use Committee (IACUC) of Hunter College. Two 
(2) cohorts of male C57Bl6 mice (N=71 total; cohort 1 n=22, cohort 2 n=49) purchased from 
Taconic Biosciences were used for this study. Upon purchase, animals were received at Hunter 
College’s Animal facility aged 6 weeks. Mice were individually housed, kept on a 12h/12h 
light/dark cycle from 7:30h to 19:30h, and fed standard rodent chow ad libitum for 1 week prior 
to handling and starting baseline assessments. Mice were housed individually to control for 
social effects of group housing 93 that could affect the voluntary consumption of 
methamphetamine in our model. 
 
3.3.2 Food restriction 
In order motivate mice to consume MA baits, strict food-restriction schedules were instituted for 
both MA and control mice. Standard rodent chow was delivered at 18:00h, at a ratio of 1g of 
chow per 5g of body weight, every day for the duration of the study. This feeding schedule 
ensured that mice would be willing to consume MA-oat baits during the VOMA administration 
window each day without disrupting weight gain or loss during the experiment, as previous work 
has reported significant circadian effects in a similar VOMA administration design 94.  
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3.3.3 VOMA 
From two (2) cohorts of mice, n=17 mice were placed into control treatment and n=54 mice were 
placed into VOMA. Daily body weights were recorded, and 1 or more dosing solutions were 
formulated for each weight class, restricted to within 5 grams of body-weight variability. 
Working MA dosing solutions of 0.8 to 0.9 mg/mL (in water) was made and prepared for 
administration. Mice were housed in standard polycarbonate cages for drug administration 
procedures. Each cage was used for the same mouse throughout the experiment to minimize 
housing stressors. Methamphetamine (0.007 mL at 1mg/kg and ~0.8mg/mL) was dissolved into 
oatmeal bran chips (Maypo Inc.) and served 16 times per day to each mouse, at 15-minute 
intervals. Control mice received water absorbed by oat chips. Experimenters administered 
individual MA-oatmeal chips to each mouse and tracked consumption before delivering new 
MA-oat baits. Administration room was kept isolated from surrounding noise and activity. 
VOMA and control administration was carried out between 12:00h and 18:00h every day for the 
duration of the experiment.  
 
3.3.4 Sensitization-induced mobility in test cage 
A subset of mice (n=12 control, n=13 low consumers and n=9 high consumers) were used for 
tests of sensitization measures. Mice were analyzed for mobility in their VOMA cage to measure 
sensitization prior to receiving MA. Mobility was defined as time mice spent running, jumping, 
walking, interacting with nests, and climbing on the bars of the cage. Three-minute videos were 
recorded of each subject. Mobility of each subject determines degree of sensitization and 
anticipation of MA delivery on day 8 (after one week of VOMA) and day 15 (one day after the 
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VOMA period). Mice did not receive MA on day 15, but rather were only exposed to their MA 
cage to capture videos and then promptly returned to their home cage. 
 
3.3.5 Radial Arm Maze Shaping and Baseline Working Memory Assessments 
The radial 8-arm maze (RAM) was used to assess both working memory and spatial learning. 
The maze consists of a center platform (15.24 cm diameter) with 8 equivalently sized arms 
radiating outward. Each arm is 38 cm in length, 6.35 cm wide with a submerged food cup (2.0 
cm diameter) at the end of each arm. Ensure was used as a food reward (0.007mL per bait). 
Prior to the start of VOMA, all animals were shaped on the RAM. Mice were food restricted to 
~85% of free feeding weight. On day 1 of RAM shaping, mice were placed on the RAM for 
5min to acclimate to the maze and room cues, with food baits available around maze and inside 
food cups. On day 2 of shaping, mice were given 15min each to explore the maze and the food 
baits on ends of maze-arms and inside cups. On day 3 baseline working memory performance 
was recorded. Mice were given 15min each to collect small baits at the ends of arms. 
Performance on days 3 was used to balance groups across treatments.  
 
3.3.6 Radial Arm Maze Working Memory Assessment  
Working memory assessment (WMA) was assessed 2 days after end of VOMA and 4 weeks into 
abstinence, for a subset of mice not slated for tissue collection (n=11 control, n=13 low 
consumers and n=8 high consumers). One (1) trial was used to assess performance at each time 
point. Before starting each trial, all food cups were baited with Ensure. To begin a trial, mice 
were confined for 30s to the center platform with a plastic cylinder. The sequence of arms 
entered to retrieve the food rewards was recorded. To prevent a non-spatial strategy, mice were 
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allowed to collect baits from up to 3 sequential arms (in any one direction around the radial 
maze) before the experimenter interrupted the chaining strategy. Errors were recorded as re-
entries into arms where the food reward has already been collected. Maximum latency for each 
trial was set at 15min.  
 
3.3.7 Radial Arm Maze Spatial Learning / Cognitive Flexibility Assessment 
28d after VOMA, a subset of mice (n=6 control, n=5 low consumers and n=6 high consumers) 
were trained on a reference memory version of the RAM as previously reported1. This paradigm 
has 4 baited and 4 un-baited arms in a pattern specific to each animal and remained constant 
throughout the experiments. Mice were given 6 consecutive trials per day for 10 days (60 trials 
total). Between trials mice were confined to the center platform while the arms were re-baited, 
and the maze cleaned. The sequence of arm entries was recorded. A reference memory error 
reflects an entry into an arm that was never baited, while working memory errors reflect re-
entries into an arm where the bait had already been collected. Mice were only be allowed to enter 
up to 3 sequential arms (in any one direction around the radial maze) to prevent the non-
hippocampus dependent chaining strategy. This version of the RAM requires mice to learn room 
cues associated with the baited and un-baited arm sequence. The training room and room cues 
were the same to those used for the WMA.  
 
3.3.8 Radial Arm Maze Retention Memory test 
The Retention Memory test used the same parameters and arm sequences used during the 
cognitive flexibility/reference memory assessment. Three (3) trials using the same baited 
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sequences from the learning assessment were used to test the memory performance of each 
mouse that underwent the reference learning paradigm. 
 
3.3.9 Tissue Collection 
Following the end of VOMA and 4 weeks days of abstinence, designated mice underwent 
controlled cervical dislocation of the skull from the spine and brain tissue was harvested. 
Hippocampi from each mouse were microdissected, snap frozen and stored at −80oC until 
processed further.  
 
3.3.10 Fractionation 
Following tissue collection, a subset of mice tissues from each consumption group were used for 
western blotting analyses (n=5 control, n=2 low-abstinence consumers, n=4 low+abstinence 
consumers, n=3 high-abstinence and n=5 high+abstinence consumers). Collected tissue was 
fractionated into cytosolic and synaptic fractions as previously reported189. Briefly, tissues were 
thawed and homogenized in a TEE (Tris 50mM; EDTA 1mM; EGTA 1mM) buffer containing 
Sigma Fast, a protease inhibitor cocktail (Sigma Aldrich) diluted to contain AEBSF (2 mM), 
Phosphoramidon (1 mM), Bestatin (130 mM), E-64 (14 mM), Leupeptin (1 mM), Aprotinin (0.2 
mM), and PepstatinA (10 mM). Tissues were homogenized in 200μl of TEE-homogenization 
buffer using 20 pumps with a motorized pestle. Homogenates were transferred to Eppendorf 
tubes and centrifuged at 3000 x g (5 min at 4° C), to remove un-homogenized tissue. The 
resulting supernatant was centrifuged at 100,000 g for 30 min. After ultracentrifugation, the 
supernatant was collected and stored as the cytosolic fraction. The remaining pellet was re-
suspended in 100μl of homogenizing TEE buffer containing 0.001% Triton X-100, incubated on 
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ice for 1hr and then centrifuged at 100,000 g for 1hr at 4°C. The resulting supernatant was stored 
at the plasma-membrane fraction. The resulting pellet was re-suspended in 50 μl of TEE buffer 
and stored as the synaptic fraction95. The Pierce bicinchoninic acid assay (BCA; Thermo 
Scientific, Rockford, IL, USA) was used to determine protein concentration for each sample. 
Samples were reduced with 4x Laemmli sample buffer equivalent to 25% of the total volume of 
the sample and then boiled and stored frozen at -80°C.  
 
3.3.11 Western Blotting Analysis 
Hippocampi were collected form mice directly following VOMA and after 4 weeks of abstinence 
(mice from each consumer groups were allocated to –Abstinence and +Abstinence sub-groups, 
balanced for MA consumption). The tissue was separated into synaptic fractions as previously 
reported1. Samples (20 μg) were loaded on to a Tris/Glycine 4–20% mini gel to resolve: GFAP 
(55 kDa), GAPDH (37 kDa), DAT (69 kDa), COX-2 (72 kDa), 5-HT2a (53 kDa.). Every gel 
contained 3-4 lanes loaded with the same control sample designated as all brain sample (ABS). 
ABS was used to standardize protein signals between gels. Gels were transferred to 
nitrocellulose membranes in the IBlot® Dry Blotting System (Life Technologies; Carlsbad, CA, 
USA) for 7 min. Nitrocellulose membranes were then incubated in blocking solution containing 
5% sucrose in Tris Buffered Saline with Tween-20 (TBST; 0.1% Tween-20 in TBS) for 30 min 
at room temperature. Samples were incubated overnight with the following primary antibodies: 
GFAP (1:2000; Abcam Inc., Cambridge, MA, USA), GAPDH (1:2000; Abcam Inc., Cambridge, 
MA, USA), DAT (1:2000; EMD Millipore, Temecula, CA, USA), COX-2 (1:2000; Santa Cruz 
Biotechnology, Santa Cruz, CA, USA), and 5-HT2a (1:2000; EMD Millipore, Temecula, CA, 
USA). Membranes were washed in TBST for 20 min and probed with Horseradish Peroxidase 
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(HRP) conjugated secondary antibodies: Goat Anti-Mouse IgG (H + L)-HRP Conjugate 
#1706516 (BioRad); Goat Anti-Rabbit IgG (H + L)-HRP Conjugate #1706515 (BioRad); Rabbit 
Anti-Goat IgG H&L (HRP) (ab6741-Abcam). Membranes were incubated with Enhanced 
Chemiluminescence (ECL) substrate and exposed on CL-X Posure Film (Thermo Scientific; 
Rockford, IL, USA). Films were scanned, and then densitometry was performed with NIH 
ImageJ 96. 
 
3.3.12 Statistics 
For behavioral analyses, a repeated measure t-test, a repeated measures ANOVA and two-way 
ANOVA was used. Post-hoc analyses used a Bonferroni-corrected t-test. For data-sets that 
included missing values due to tissue collection attrition designs, a Type III Mixed Effects model 
analysis design was used. Molecular analyses used a One-way ANOVA and Bonferroni 
corrected post-hoc comparisons. Prism GraphPad 7.0 (La Jolla, California) was used for all 
statistical analyses.  
 
3.4 Results 
3.4.1 VOMA models naturalistic MA consumption 
The experiment was conducted over 10 weeks, with VOMA running for 14d during study weeks 
1 and 2. Behavior Assessments were carried out throughout the experiment. Tissue collection for 
western blot analyses occurred after 14-day VOMA and after 4 weeks of abstinence (Fig11A). 
Consumption of each subject was recorded throughout the 14-day VOMA period (Fig11B). 
Tracking of consumption revealed distinct consumer classes in mice. Subjects were split into two 
distinct groups for respective behavioral and neurochemical analyses: high and low consumers. 
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High consumers averaged 2.36 mg/kg per day (n=34; 33.15 mg/kg total over 14d). Low 
consumers averaged 1.39 mg/kg per day (n=20; 19.4 mg/kg total over 14d). Both groups’ 
consumption rates dropped from week 1 to week 2, suggesting a failure in producing sustained 
MA preference in this experiment. A Two-way repeated measures ANOVA of MA consumption 
rates between the groups revealed an effect of day (F13, 676=21.69, p<0.001) and effect of 
group (F1,52=33.94, p<0.001). Post hoc comparisons revealed significant differences on days 
1,2,3,4,6,7,8,9,10,11 and 12 (p>0.05). Weights of each subject was measured throughout the 
whole experiment (Fig11C). A Type III mixed effects model was run to analyze body weights of 
all groups throughout the experiment. A significant effect of day was observed (F9,420=121.1, 
p<0.001). No significant effects between groups were observed.  
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Figure 10. Experimental design, Methamphetamine consumption and Body weights. (A) 
Over 10 weeks, mice were assessed for various behavioral measures, put through 14 days of 
VOMA, and tissue collected (red asterisks*) at designated timepoints. (B) Consumption of each 
subject was recorded throughout the 14-day VOMA period. Due to the wide range of 
consumption rates, mice were split into two distinct groups: high (n=34) and low (n=20) 
consumers. High consumers averaged 2.36 mg/kg per day (33.15 mg/kg total over 14d). Low 
consumers averaged 1.39 mg/kg per day (19.4 mg/kg total over 14d). Both groups’ consumption 
rates dropped from week 1 to week 2, suggesting a failure in producing sustained MA preference 
in this experiment. (C) Weights of each subject was measured throughout the whole experiment. 
No significant difference was found between each of the groups. 
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3.4.2 VOMA consumers show transient sensitization 
The mobility of mice in their respective drug-administration cages prior to starting any VOMA 
procedures may serve as a measure of sensitization and potentially, anticipation of MA 
administration. Three (3) minute videos were captured for n=12 control, n=13 low consumers 
and n=9 high consumers inside their drug administration cages before the start of any VOMA 
procedures. Blinded observers quantified each video for mobility of each mouse. A One-way 
ANOVA of mobility at the end of week 1 revealed a significant overall effect of group 
[F2,31=6.699; p<0.005]. Post hoc analyses revealed significant differences between High 
consumers (**) vs. low consumers (p<0.05) and, separately, High consumers vs controls 
(p<0.005) (Fig 12A). A One-way ANOVA of mobility at the end of week 2 revealed no 
significant group effects (Fig 12B). 
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Figure 11. VOMA-induced sensitization. VOMA-Cage mobility prior to start of VOMA 
delivery indicates sensitization to MA and potentially anticipatory awareness of VOMA delivery. 
(A) Week 1 mobility analysis revealed a significant overall effect of treatment. Post hoc analyses 
revealed significant differences between High consumers (n=9; **) vs. low consumers (n=13; 
p<0.05) and controls (n=12; p<0.005).  (B) Week 2 mobility analyses revealed no significant 
overall effect of treatment.  
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3.4.3 VOMA produces acute spatial working-memory deficit not present during abstinence 
Working memory assessments were run prior to and after VOMA. Baseline working memory 
assessments were used to balance groups into either VOMA or control. A subset of mice for used 
to test working memory performance over the course of the study (n=11 control, n=13 low 
consumers and n=8 high consumers). Baseline performance for these mice shows no appreciable 
difference between groups (Fig 13A; 2days, 1 trial per day). A Two-way ANOVA of WM 
Baseline performance between control mice and Low Consumers revealed a significant effect of 
bait (F1,22=158.6; p<0.001) and no significant effect of treatment. A Two-way ANOVA of WM 
Baseline performance between control mice and High Consumers revealed a significant effect of 
bait (F1,17=107.8; p<0.001) and no significant effect of treatment. A Two-way ANOVA of WM 
Baseline performance between High Consumers and Low Consumers revealed a significant 
effect of bait (F1,19=133.3; p<0.001) and no significant effect of treatment. Directly following 
VOMA, 1 WM trial was run for all mice (Fig 13B). A Two-way ANOVA of WM performance 
after VOMA between control mice and Low Consumers revealed a significant effect of bait 
(F1,22 =82.49; p<0.001) and no significant effect of treatment. A Two-way ANOVA of WM 
performance after VOMA between control mice and High Consumers revealed a significant 
effect of bait (F1,17 =72.03; p<0.001) and a significant effect of treatment (F1,17 =5.096; 
p<0.05). Post-hoc comparisons of performance between groups in each bait-group revealed a 
marginal difference between groups on baits 5-8 (t34=2.194, p=0.07). A Two-way ANOVA of 
WM performance after VOMA between High Consumers and Low Consumers revealed a 
significant effect of bait (F1,19 =154.4; p<0.001) and a significant effect of treatment (F1,19 
=6.176; p<0.05). Post-hoc comparisons of performance between groups in each bait-group 
revealed a significant difference between groups on baits 5-8 (t38=2.46, p<0.05). Following a 4-
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week abstinence period, 1 more WM trial was run for all mice (Fig 13C). A Two-way ANOVA 
of WM performance between control mice and Low Consumers revealed a significant effect of 
bait (F1,22 =61.27; p<0.001) and no significant effect of treatment. A Two-way ANOVA of 
WM performance between control mice and High Consumers revealed a significant effect of bait 
(F1,17 =50.48; p<0.001) and no significant effect of treatment. A Two-way ANOVA of WM 
performance between High Consumers and Low Consumers revealed a significant effect of bait 
(F1,19 =34.69; p<0.001) and no significant effect of treatment.    
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Figure 12. Working Memory Assessment. Working memory performance was tracked for a 
subset of mice across the study. (A) Baseline performance is not different between treatment 
groups. (B) After VOMA, 1 WM test revealed that High consumers performed significantly 
worse than control and low consumers (*). (C) After 4 weeks of abstinence, WM performance 
was no different between treatment groups.  
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3.4.4 Abstinence does not affect RAM spatial learning 
A subset of mice (n=6 control, n=5 low consumers and n=6 high consumers) were chosen to 
undergo further cognitive testing on the RAM. Mice underwent spatial-reference memory 
training over a 10d period (Fig 14A). A Two-way ANOVA of learning performance between 
control mice and Low Consumers revealed a significant effect of day (F9,81=12.96, p<0.001) 
but no significant effect of treatment. A Two-way ANOVA of learning performance between 
control mice and High Consumers revealed a significant effect of day (F9,72=12.24, p<0.001) 
but no significant effect of treatment. A Two-way ANOVA of learning performance between 
High Consumers and Low Consumers revealed a significant effect of day (F9,63=11.06, 
p<0.001) but no significant effect of treatment. A Two-way ANOVA of reference-memory errors 
between control mice and Low Consumers revealed a significant effect of day (F9,81=21.12, 
p<0.001) but no significant effect of treatment (Fig 14B). A Two-way ANOVA of reference-
memory errors between control mice and High Consumers revealed a significant effect of day 
(F9,72=14.43, p<0.001) but no significant effect of treatment. A Two-way ANOVA of 
reference-memory errors between High Consumers and Low Consumers revealed a significant 
effect of day (F9,63=11.08, p<0.001) but no significant effect of treatment. A Two-way ANOVA 
of working memory errors control mice and Low Consumers revealed a significant effect of day 
(F9,81) =3.739, p < .001), no significant effect of treatment, and a significant interaction of day 
and treatment effect (F9,81=2.408, p<0.05). Post hoc comparisons found no significant 
differences between groups. A Two-way ANOVA of working memory errors control mice and 
High Consumers revealed a significant effect of day (F9,72) =5.888, p < .001) but no significant 
effect of treatment. A Two-way ANOVA of working memory errors High Consumers and Low 
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Consumers revealed a significant effect of day (F9,63) =4.236, p < .001) but no significant effect 
of treatment (Fig 14C). 
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Figure 13. Reference Memory Assessment. (A) Reference memory assessment shows an 
overall effect of day within first five days of learning but not within the last five days of learning, 
after running a Two-way ANOVA. This indicates a more drastic increase in learning in the first 
five days compared to the last four. (B) All mice showed a gradual decrease in reference errors 
over time that was not significant between groups. (C) Working memory errors made throughout 
19d of training were not different between groups.  also gradually decreased, indicating a general 
improvement of memory and performance throughout the experiment.  
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3.4.5 Abstinence does not affect RAM retention memory 
Eight (8) days after the end of the RAM reference-training phase, mice were put back on the 
maze to complete a retention test of the memory learned during the training period within 3 
trials. A One-way ANOVA of the performance on the RAM revealed no significant differences 
between groups (Fig 15A). A One-way ANOVA of the reference-memory errors revealed no 
significant differences between group (Fig 15B). A One-way ANOVA of the working-memory 
errors revealed no significant differences between groups (Fig 15C). These results highlight the 
behavioral resilience and plasticity that subjects experience during abstinence.  
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Figure 14. Retention Memory Test. Eight (8) days after the end of RAM training, a retention 
test was run for all mice. (A) Performance on the tests was not significantly different between the 
treatment groups. (B) Reference memory errors during the retention test were not significantly 
different between the treatment groups. (C) Working memory errors during the retention test 
were not significantly different between the treatment groups. 
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3.4.6 Abstinence upregulates neuroinflammation in the hippocampus 
Western blot analyses of hippocampal tissue followed. A One-way ANOVA of GFAP revealed 
an overall effect of group (F4,16 =5.734; p<0.01) and controlled post hoc analyses revealed that 
the high consumption group significantly decreased GFAP compared to controls (*; p<0.05) and 
that abstinence in the same consumption group brought GFAP levels closer to control (Fig 16A).  
A One-way ANOVA of COX-2 across groups revealed an overall effect of treatment (F4,16 
=8.897; p<0.001) and controlled post hoc comparisons revealed significant differences between 
control mice and the high consumption mice that underwent abstinence (*; p<0.01) (Fig 16B). 
These results highlight the progression of neuroinflammation in the brain that occurs during 
abstinence.  
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Figure 15. Neuroinflammation increases after prolonged abstinence following VOMA. (A) 
VOMA decreases GFAP levels in the hippocampus of high consumers and abstinence modulates 
its levels closer to control. (B) Abstinence increases COX-2 levels significantly in high 
consumers compared to other treatment groups.  
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3.4.7 Abstinence decreases DAT and increases 5-HT2a in the hippocampus 
A One-way ANOVA of hippocampal DAT revealed an overall effect of treatment (F4,14 
=5.902; p<0.01) and post hoc analyses revealed a significant difference between control mice 
and High consuming mice that underwent abstinence (**; p<0.01) (Fig 17A). A One-way 
ANOVA of hippocampal 5HT2A revealed an overall effect of treatment (F4,13 =17.4; p<0.001) 
and post hoc analyses revealed a significant difference between control mice and High 
consuming mice that underwent abstinence (***; p<0.01) (Fig 17B). These results highlight the 
progressive dysregulation of monoamine protein expression that occurs as a result of abstinence.  
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Figure 16. Synaptic Monoamine proteins are modulated after prolonged abstinence. (A) 
Hippocampal DAT decreases appreciably directly in high consumers after VOMA but 
significantly decreases after a prolonged abstinence period. (B) Hippocampal 5HT2a does not 
change following VOMA, but abstinence increases its expression significantly in high 
consumers. 
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3.5 Discussion 
3.5.1 Acute VOMA models naturalistic MA abuse 
To investigate the progression of behavioral, and neurochemical changes produced by MA and 
abstinence, we used the VOMA model to put mice through 14 days of MA administration prior 
to starting abstinence. High consumers averaged 2.36 mg/kg per day (33.15 mg/kg total over 
14d). Low consumers averaged 1.39 mg/kg per day (19.4 mg/kg total over 14d). Additionally, 
both groups’ consumption rates dropped from week 1 to week 2, suggesting that this model 
produced declining MA preference. This claim is supported by our data showing different 
sensitization-induced mobility across the drug administration weeks (Fig 12). The distribution of 
Low and High MA consumers in this study confirms our hypothesis that VOMA can model 
naturalistic MA abuse. Recent studies have begun to delineate the genetic risks associated with 
MA preference201-202. However, we cannot discount environmental factors within our study 
design affecting MA preference. Pavlovian conditioning studies in humans have shown that 
extinction procedures can quickly decrease preference for MA203, while the number of drug 
presentation only modestly increase drug-induced responding204. Thus, more work is needed to 
understand the variables that produce various rates of drug consumption within VOMA.  
 
3.5.2 Behavioral changes following MA abuse 
Our behavioral analyses following VOMA revealed that High consuming mice exhibited an acute 
spatial working-memory deficit directly after the drug administration period but not during 
abstinence. This suggests that the cognitive deficits induced by 14 days of VOMA are only 
transient and further, that the adolescent mouse brain has sufficient plasticity to overcome this 
deficit. This claim is strengthened with the data from the spatial learning paradigm where MA 
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mice showed no reference memory or retention deficits during a prolonged abstinence period (Fig 
14). Future studies should compare the long-term cognitive effects of this VOMA design on adult 
vs adolescent mice. Previous studies have shown that MA administration can produce cognitive 
deficits after 1 or 3 weeks of abstinence following 16mg/kg MA administered over an 8hr period104, 
113 and throughout 3 weeks of abstinence following 14 days of 24mg/kg MA administration per 
day (but not directly after MA administration)114. Additionally, a comparative study examining the 
effects of 13 days of escalating doses of MA on single-day binge MA (up to 16mg/kg MA) vs a 
single-day binge alone showed that the addition of escalating MA doses over multiple days 
prevented cognitive deficits produced by binge MA after 1 week of abstinence74. A previous 
experiment from our lab observed cognitive deficits following MA administration after 7 weeks 
of abstinence following 2x 30mg/kg MA doses (but not before)1, Thus, it seems that MA can 
negatively affect cognition depending on the MA administration design and the timing of 
assessments following MA administration. 14 days of VOMA may prove insufficient to produce 
any robust cognitive deficits within the timeline of the present study, as the administration design 
spreads out doses over many hours per day, over 2 weeks, similar to previous studies using 
escalating MA doses74, 205. Nevertheless, having observed neurochemical changes after 4 weeks of 
abstinence in the present study, the cognitive deficits could have developed shortly after the tissue 
was collected. Future studies should characterize the cognitive performance of mice under this 
model at later timepoints, comparable to those of previous studies1. 
 
3.5.3 DAT as a clinical marker of interest for MA abuse and abstinence  
Our current study shows that VOMA decreases DAT in High consumers that received abstinence. 
High consumers that received no abstinence before tissue collection showed decreased DAT levels 
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but not to the extent of abstinent mice. These results indicate that abstinence plays a major role in 
the reduction of DAT levels following VOMA. Our previous studies showed that acute neurotoxic 
doses of MA (2x 30 mg/kg) followed by 6 weeks of forced abstinence produce long-lasting 
decreases in dopamine marker expression in the hippocampus1. Previous studies of DAT 
availability in the brains of human MA users show recovery of DAT levels206 as well as sustained 
decreases in levels207 during abstinence. Reduction in dopamine terminals and transporters are 
known to be an increased risk-factor for Parkinson’s Disease 33-34, suggesting that VOMA can 
model neurodegenerative changes in the brain. Decreases in DAT levels can indicate decreases in 
DA terminal function and density in the brain208. We hypothesize that decreased DA availability 
following MA abuse can lead to activation of compensatory mechanisms , such as increased 
5HT2a-depepdent DA release209. Previous studies indicate that 5HT2a crosstalk with DA 
pathways can affect synaptic plasticity, learning and memory210-211. However, the role of 5HT2a 
upregulation during abstinence following VOMA is unclear and should be explored in future 
research. Additionally, MA can increase astrocytosis via DAT-dependent neurotoxicity, as mice 
lacking the transporter do not show increased GFAP mRNA or immunostaining116. In the present 
study, GFAP levels are decreased after VOMA and return to control levels after abstinence (Fig 
16), suggesting that astrocyte-dependent neurotoxicity was attenuated in these mice. Previous 
research shows that GFAP levels increase following MA exposure,  within a week after a bolus 
30mg/kg MA dose126 and following a 5-day, 3x daily binge of 5mg/kg MA 212, with concomitant 
decreases in DAT levels. VOMA may produce a delayed and longer-lasting shift in astrocyte 
activity that could polarize glial signaling to the neurotrophic/A2 end of the spectrum213-214, 
resulting in partial neuroprotection of DA terminals in the long-term. Future research should 
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characterize the effects of A1 and A2 astrocyte signaling on DAT levels and DA terminal health 
following MA exposure.  
 
3.5.4 5HT2a signaling in MA abuse 
Our study also reveals that abstinence increases 5HT2a levels in the hippocampus. In the context 
of drug addiction, 5HT2a is known to play a major role in the development of cocaine 
sensitization215-216, and chronic MA upregulates 5HT2a in the medial prefrontal cortex, perirhinal 
cortex, and dorsal hippocampus217-218, brain regions pivotal to executive function and memory. 
Current studies on the potential of 5HT2a as a pharmacological target within studies of MA 
abuse are inconclusive217, 219-220, but previous work has shown that this receptor  underlies the 
reinforcing properties of MDMA221. In The 5HT2a receptor is also known to play roles in 
learning and memory (see review222) as well as aberrant cognitive processes as seen in 
psychiatric disorders200. Whereas presynaptic 5HT2a may regulate neurotransmitter release209, 
post-synaptic localization may underlie pivotal molecular signaling needed to promote learning 
and memory222, such as diaglycerol-IP3 and ERK pathways. The 5HT2a-dependent signaling 
that follows chronic MA abuse has not been explored. However, the increased levels of 5HT2a 
observed during a long-term abstinence in the current study suggest that the changes on this 
receptor may underlie the behavioral performance observed on the RAM tasks. The result also 
suggests that these mice may have developed a latent re-sensitization during abstinence as a 
result of the increased 5HT2a. Future studies should characterize the changes in this receptor in 
addiction-related brain regions, such as the NAc, PFC and others. Additionally, several lines of 
evidence have linked auto-receptor, 5HT1b, function to MA addiction223-225.   We hypothesize 
that in the context of chronic voluntary MA abuse, 5HT2a-dependent drug sensitization is 
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modulated in direct response to 5HT1b auto-receptor activity. This idea is consistent with 
preliminary, unpublished data from 5HT1b KO VOMA studies showing that female KO mice 
consume less MA over 28 days compared to male KO mice (Appendix I). This result suggests 
that 5HT1b KO mice have a loss of auto-receptor function in the brain that may require less MA 
to produce euphoric effects and/or that these mice must adopt increased self-regulation due to 
aversive effects of MA abuse. Future studies should examine the effects of VOMA on 5HT2a 
expression in these mice across sexes.  
 
3.5.5 Chronic neuroinflammatory pathways in the context of MA  
Analyses of COX-2, the inducible pro-inflammatory enzyme responsible for downstream 
inflammatory activity226, revealed that High consumers that received 4-weeks of abstinence 
showed significantly increased levels compared to controls. Non-abstinent mice showed 
comparably lower COX-2 levels compared to controls. Unpublished data from studies using bolus 
(60mg/kg total) MA have revealed that 7 weeks of abstinence upregulates COX-2 and ubiquitin 
expression in the hippocampus (Appendix II). These data suggest that inflammation might be 
exacerbated during long periods of abstinence, despite not showing differences shortly after MA 
exposure. MA-induced neurotoxicity can activate microglia early on after MA abuse227, that can 
induce inflammatory molecular signaling detrimental to neuronal function (reviewed in45). Acute 
neuroinflammation is essential to neuronal survival, but repetitive activation of neuroinflammatory 
responses may contribute to neurodegenerative processes, as seen in many neurodegenerative 
disease models228-229.  Pro-inflammatory pathways include cyclooxygenases, specifically COX-2 
which produces neurotoxicity after MA abuse73. COX-2 upregulation can form a chronic 
inflammatory feedback loop with prostaglandin J2 (PGJ2)161. PGJ2 is a highly neurotoxic 
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prostaglandin 157, as it impairs both the ubiquitin-proteasome pathway 158-159 and mitochondrial 
function 160, leading to aggregation of ubiquitinated proteins and failure of protein turnover. This 
mechanism provides one pathway that neuroinflammation can transition from acute to chronic 
states230. Previous work using our VOMA model investigated the changes in prostaglandin levels 
in mice hippocampi. Mass spectrometry analyses revealed that a cohort of male C57 mice that 
consumed an average total of 25.8 mg/kg MA over 14 days of VOMA showed increased PGJ2 
levels in the hippocampus after 4-weeks of abstinence189. In the same study, mice that were 
injected with 60 mg/kg MA over 2 weeks also showed increased PGJ2 levels in the hippocampus 
after a prolonged abstinence period. Previous studies have shown that chronic unpredictable stress 
and MA can interact to significantly increase COX-2 in the cerebral vasculature within 1 week of 
abstinence231. Recent evidence indicates that microglial and COX-2 play major roles in 
dopaminergic neurotoxicity 1 week after an ethanol and MA challenge232. Our current study 
reveals that even low doses of VOMA over 2 weeks can produce a delayed increase in COX-2, 
observed 4 weeks into abstinence. This delayed neuroinflammatory response may reflect a latent 
susceptibility to MA-induced changes. Future studies should investigate the effects that increased 
COX-2 may have on parallel immune pathways such astrocyte activity, which is known to 
participate in crosstalk with the primary proinflammatory mediators, microglia233.  
 
3.5.6 Neuroglial activity following MA abuse 
Finally, analyses of GFAP expression, a marker of astrocyte activation234, revealed that VOMA 
significantly decreases its levels and that abstinence brings its expression comparably closer to 
baseline levels (Fig 16). MA-induced reductions of DAT may indicate degeneration of DA axonal 
terminals 121-124. This explanation is supported by increased activation of astrocytes associated with 
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MA treatment 122, 125-126. Increases in GFAP have been observed at 24h post neurotoxic MA 
administration and decrease 7 days after injection235. Increases in GFAP may indicate a 
regenerative response in the brain146, and suggests that this neuroinflammatory response works to 
regenerate MA-induced neurochemical deficits. Previous work on MA-induced effects on 
neuroglia have found that acute MA can induce a polarized neurochemical activation in microglia 
to M1, or proinflammatory, while decreasing their M2, or neurotrophic, activity236  Similarly, two 
types of astrocyte populations have been reported during neuroinflammation: A1 astrocytes are 
pro-inflammatory and neurotoxic237 and A2 astrocytes secrete neurotrophic factors to promote 
neuroprotection213.  Previous work in brain injury models indicate that various pathways could 
promote neuroprotective activity by astrocytes238-240. Future research should elucidate the 
expression of A1 and A2 astrocyte populations following VOMA and abstinence. 
 
3.6 Conclusion and Clinical Implications 
Our study characterizes a time-course of behavioral and molecular deficits that occur following 
voluntary oral administration of methamphetamine. Our VOMA study provides evidence that 
low doses of voluntary MA do not produce long-lasting behavioral deficits. Neurochemical 
analyses showed that VOMA produced only a significant decrease in GFAP levels. Tissue 
collected after 1 month of abstinence revealed more changes in monoamine protein and 
neuroinflammatory marker expression. These results suggest that despite receiving low doses of 
MA, VOMA can model long-lasting neurochemical changes that may reflect susceptibilities to 
neurodegenerative processes present during abstinence. Our data provide new avenues of 
research to investigate the neurochemical changes that ensue during abstinence periods, and its 
effects on behavior and cognition in-vivo. 
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4.1 Abstract 
Studies show that females exhibit increased susceptibilities to psycho-stimulant addiction 
compared to males. Additionally, adolescence may contribute to female-specific vulnerabilities 
to addiction. However, little is known about the underlying mechanisms in the brain that produce 
this vulnerability in adolescent female populations. To model methamphetamine addiction, we 
used a mouse model for voluntary oral methamphetamine administration, (VOMA). Previous 
work suggests VOMA can model voluntary consumption that mirrors human binge patterns over 
28 consecutive days, unlike other models that utilize bolus doses over shorter periods of time. 
Additionally, our current study used an escalating-dose regimen over the first 10d to maximize 
the administration rate over the remaining 18d of VOMA. Over the course of 28d, we found that 
male mice consumed an average 4.67 mg/kg/day over 28d and female mice consumed an 
average 5.84 mg/kg/day over 28d. In order to evaluate differential neurotoxic effects of MA 
between sexes, we focus on medium consumers of MA whose consumption rates across both 
sexes were not significantly different: male mice consuming an average 7.68 mg/kg/day over 28d 
and female mice consuming an average 8.2 mg/kg/day over 28d. Following VOMA, behavioral 
assessments revealed that VOMA did not alter depression in the tail suspension task but 
decreased anxiety in both sexes on the elevated plus maze (EPM).  VOMA females, but not 
males, showed increased exploratory behavior on the EPM.  In a hippocampal dependent 
working memory task (radial arm maze), adolescent female, but not male, VOMA mice show 
working memory deficits. The sex-specific behavioral changes occurred while both sexes 
voluntarily consumed equivalent amounts of MA. The behavioral results occur in tandem with 
sex-specific neurochemical changes in the hippocampus, specifically involving glycogen 
synthase kinase-3 beta (GSK3β)-associated molecular activity. Male, but not female, adolescent 
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mice exhibit neuroprotective molecular changes in response to VOMA including increases in 
dopamine receptor 1 (D1), estrogen receptor alpha (ERα) phosphorylated Akt (pAkt), and 
pGSK3β/GSK3β ratio. Further, females show an increase in D-prostanoid receptor 1 (DP1) 
levels and a concomitant increase in kappa opioid receptor (OR) in the nucleus accumbens 
(NAc) suggesting a response to increased neuroinflammation that males do not exhibit. These 
results suggest that an escalation MA administration protocol may potentiate the sex-differences 
in neurochemical resilience observed in male, but not female adolescent mice. The results further 
indicate that female mice show molecular deficits in the brain compared to males.  Our study 
reveals that female mice show specific susceptibilities to methamphetamine challenges and offer 
potential molecular mechanisms for this phenomenon.  
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4.2 Introduction 
Methamphetamine is a highly addictive psychostimulant, showing higher rates in adolescent 
females compared to adult female lifetime users 241. Clinical reports indicate that females begin 
using MA recreationally at a younger age, and transition more quickly to MA addiction that 
leads to intravenous use compared to males 242. Female MA users also reported greater severity 
of drug use and psychological burden than males 243, including increased rates of depression, 
psychosis, and suicide 244-246. In males, but not females, drug craving was correlated with 
depression and anxiety 247. Recent reports show females have sustained vulnerability to the 
neurotoxic effects of MA following prolonged abstinence, showing greater reductions in 
hippocampal volumes and wide-spread reduction in grey matter compared to control females, 
whereas no difference was observed between METH-abusing and control male subjects 248-249.  
 
Rodent studies have also identified sex-differences in MA self-administration 250 251. Female rats 
show accelerated MA self-administration compared to males 252-254 and more rapidly reinstated 
drug-seeking compared to males 253, 255. While few studies have identified signaling mechanism 
associated with sex-dependent drug seeking behaviors 256-257, even fewer studies have identified 
the neurochemical effects of long-term or chronic MA on adolescent male and female mice 78-80. 
Therefore, the current study investigated the chronic behavioral and neurochemical 
consequences of voluntary oral methamphetamine administration (VOMA) in adolescent male 
and female mice. 
 
Our study focuses on select signaling pathways and synaptic markers that are known to be 
selectively affected by MA.  Previous studies have identified acute and chronic deficits in 
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dopamine related markers following binge and VOMA models 118, 189, 258. Thus, we examined the 
effects of the dopamine transporter (DAT), the dopamine precursor tyrosine hydroxylase (TH) 
and the dopamine receptor 1 and 2 (D1, D2) in hippocampus following chronic MA. The effect 
of neurotoxic or binge dosing of MA shows increased susceptibility in males than females as 
observed by more extensive striatal DA reduction and larger decreases in DAT 78, 259-261.  These 
studies suggest a role for estrogen as an underlying neuroprotective mechanism and are 
consistent with the report on BALB/c mice showing greater MA-induced vulnerability in females 
during diestrus (low estrogen) compared to proestrus (high estrogen) 260. Based on these 
findings, we evaluated the long-term consequences of chronic VOMA on ERα and its 
downstream activation of Akt and GSK3β signaling pathways.  Since MA produces different 
effects on dopaminergic markers in female and male mice, these findings provide important new 
information related to the signaling pathway differences in toxicity induced by chronic MA 
exposure. To examine potential dysphoric effects between males and females during 2 weeks of 
abstinence after chronic 28d MA, we evaluated the expression of the −opioid receptor (OR) 
and D1 in the NAc. 
 
Additionally, our study focuses on the sex-differences in hippocampal molecular signaling. 
Previous studies have revealed that rodents activate distinct molecular cascades across the sexes 
following hippocampal-dependent spatial training 262-263. Available evidence indicates that 
female spatial learning is influenced greatly by fluctuations in gonadal hormone availability 
throughout the estrous cycle, with optimal performance observed during the proestrus phase 264, 
and is thought to be driven by proliferative molecular signaling in the hippocampus 264. More 
recently, it has been shown that female mice exhibit heightened corticosterone responses 
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following MA challenges compared to males, driven by hippocampal and hypothalamic HPA-
axis dependent glucocorticoid signaling 265. These findings suggest that females may be 
specifically vulnerable to MA-induced cognitive deficits and neurochemical shifts. 
 
We focus our analysis on groups of males and females that voluntarily consumed equivalent 
amounts of MA.  Our results show that following 28d VOMA, females show a deficit in spatial 
working memory performance, but males do not. VOMA males show increased hippocampal D1 
with a concomitant increase in ERα and enhanced downstream signaling including pAkt and the 
pGSK3β/GSK3β ratio, but females do not. VOMA females show elevated D-prostanoid receptor 
1 (DP1) and a decrease in DP2 suggesting elevated neuro inflammation. In the NAc, females 
show lower levels of D1 and increased κOR in VOMA females compared to female controls. 
These findings highlight the differential effects and elevated vulnerability of the adolescent 
female to the neurotoxicity of chronic MA and possibly enhanced dysphoric effects during 
abstinence which contribute to our understanding of the neural mechanisms that may underlie 
differential vulnerabilities to MA between sexes. 
 
4.3 Methods 
 
4.3.1 Animals 
 
Male (n=20) and female (n=20) C57/bl6 mice were purchased from Taconic Biosciences and 
were received at Hunter College’s Animal facility at 6 weeks of age. Mice were individually 
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housed, kept on a 12h/12h light/dark cycle from 7:30h to 19:30h, and fed ad libitum for 1 week 
prior to handling.  
 
4.3.2 Food restriction 
 
At the start of their 2nd week in the facility, mice were transitioned from ad libitum food to being 
fed daily rodent chow that weighed 20% of the average body weight (approx. 4g chow for males 
and 3.5g chow for females per day). For RAM assessments, weights were recorded for 5d and 
diets were restricted until mice reached 85% of their baseline BW.  Working memory assessment 
on the 8-arm Radial Maze, lasted 4d total with shaping and baseline assessments included. 
Following RAM memory assessments, mice were fed daily rodent chow that weighted 20% of 
the average BW.  Feeding mice daily chow weighing 20% of their BW allowed for a continuous 
increase in BW reflecting growth (Fig 1). 
 
4.3.3 Radial 8-arm Maze Shaping/Baseline 
 
The radial 8-arm maze (RAM) was used to assess spatial working memory. The maze consists of 
a center platform (15.24 cm diameter) with 8 equivalently sized arms radiating outward. Each 
arm is 38 cm in length, 6.35 cm wide with a submerged food cup (2.0 cm diameter) at the end of 
each arm. Maypo (Homestat Farm, Dublin, OH) was mixed in water to make a wet mash that 
that was used as a food reward (0.02 g portions), as previously described for mice 189 and rats 88. 
On day 1 of RAM shaping, mice were placed on the RAM for 5 min to acclimate to the maze 
and room cues, with food baits available around maze and inside food cups. On day 2 of shaping, 
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mice were given 15 min each to explore the maze and the food baits on ends of maze-arms and 
inside cups. On days 3 and 4 of shaping, mice were given 15 min each to collect small baits at 
the ends of arms. Performance on days 3 and 4 was recorded and used to balance groups across 
conditions based on baseline RAM performance.  
 
4.3.4 Working Memory Assessment  
 
After 4d of abstinence mice underwent working memory assessments (WMA). Mice were tested 
over 2 days (1 trial/day). Each trial started with all food cups baited. To begin each trial, mice 
were confined for 30s to the center platform with a plastic cylinder. The sequence of arms 
entered to retrieve the food rewards was recorded. To prevent a non-spatial strategy, chaining, 
mice were allowed to collect baits from up to 3 sequential arms before the experimenter 
interrupted the chaining strategy. Working memory errors were recorded as re-entries into arms 
where the food reward has already been collected. Maximum latency for each trial was set at 15 
min. 
 
4.3.5 Tail Suspension 
 
After 5 days of abstinence, mice underwent behavioral assessments. To assess for depressive 
phenotypes, we used the tail-suspension test. Mice were hung by their tails and suspended three 
feet in the air. Mice were kept suspended for six minutes and videos were recorded. Video 
scorers were blinded to the animals’ experimental condition. Scorers tracked and recorded the 
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time spent immobile for each mouse. Immobility was considered any lack of voluntary taxis or 
body movements, including the torso, limb, or head. 
 
4.3.6 Elevated Plus Maze 
 
After 7d of abstinence, mice were placed on the elevated plus maze (EPM) assessment. This 
behavioral assay assesses anxiety and related behavioral phenotypes. Lighting conditions on and 
around the EPM inside the testing room were kept consistent for all mice. Lux was maintained 
high (average 200 lux on and around EPM) to measure for anxiolytic effects of chronic MA 
exposure 266. Following a 15-minute acclimation to the testing room, each mouse was placed 
onto the center of the EPM, facing an open arm opposite from the experimenter. The mouse was 
allowed to explore the EPM for 8 minutes. Videos were recorded for each mouse. Video scorers 
quantified the number of open and number of closed arm entrances for each mouse. Arm entries 
were scored when all four mouse paws crossed into the 75% remaining length of an arm (from 
the center to the end).  
 
 
4.3.7 MA formulation 
 
A stock solution 40mg/mL of methamphetamine hydrochloride (Sigma Aldrich) was formulated 
using de-ionized water. Daily body weights were used to calculate working volumes of Ensure-
MA solutions for each weight class. From 40mg/mL stock, Ensure-MA solutions were delivered 
to mice in 7μL containing a maximum dose of 1mg/kg bw MA.  
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4.3.8 Voluntary oral methamphetamine administration 
 
A cohort of 40 mice (n=20 per sex) were assigned into drug and control groups, balanced across 
treatments with bw and baseline working memory performance. VOMA groups contained n=14 
mice per sex and Control groups (no MA, Ensure only) contained n=6 mice per sex. On the 15th 
day following their arrival, mice began the Escalation phase of VOMA: 3 days of 1 dose/day at 
0.25 mg/kg MA per bait; 3 days of 4 doses/day at 0.25 mg/kg MA per bait; 2 days of 16 
doses/day at 0.25 mg/kg MA per bait; and 2 days of 16 doses/day at 0.5 mg/kg MA per bait. 
From day 11 to day 28 of VOMA, mice received 16 doses/day at 1 mg/kg MA per bait.  Doses of 
MA were delivered at 15 min intervals for a total period of administration lasting 4 h. Following 
each bait presentation, the number of consumed bait was recorded for each animal. Control mice 
had untreated Ensure delivered at the same bait/hour/day rate as MA treated mice.  
 
4.3.9 Tissue sample collection and fractionation  
 
Following 28d of VOMA and 15 days of abstinence where behavioral testing was done, 
hippocampal and nucleus accumbens (NAc) tissue from all animals were collected on day 15 of 
abstinence. Tissues were flash frozen on dry ice. To fractionate tissue into cytosolic and synaptic 
fractions as previously reported 258. Briefly, tissues were thawed from frozen and homogenized 
in a TEE (Tris 50 mM; EDTA 1 mM; EGTA 1 mM) buffer containing a SigmaFast, protease 
inhibitor cocktail (Sigma Aldrich) diluted to contain AEBSF (2 M), Phosphoramidon (1 M), 
Bestatin (130 M), E-64 (14 M), Leupeptin (1 M), Aprotinin (0.2 M), and Pepstatin A (10 
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M).  Tissues were homogenized in 200 l of the TEE-homogenization buffer using 20 pumps 
with a motorized pestle.  Homogenates were transferred to Eppendorf tubes and centrifuged at 
3,000 g (5 min at 4o C), to remove unhomogenized tissue.  The resulting supernatant was 
centrifuged at 100,000 g for 30 min.  After ultracentrifugation, the supernatant was collected and 
stored as the cytosolic fraction.  The remaining pellet was resuspended in 100 l of 
homogenizing TEE buffer containing 0.001% Triton X-100, incubated on ice for 1h and then 
centrifuged at 100,000 g for 1h at 4° C. The resulting pellet was resuspended in 50 l of TEE 
buffer and stored as the synaptic fraction 95.  The Pierce bicinchoninic acid assay (BCA) 
(Thermo Scientific, Rockford, IL) was used to determine protein concentration for each sample. 
Samples were reduced with 4x Laemmli sample buffer equivalent to 25% of the total volume of 
the sample and then boiled and stored frozen at -80o C.   
 
4.3.10 Protein quantification and western blot assessments 
   
Samples (20 g) were loaded onto a Tris/Glycine 4-20% midi gel to resolve gapDH (36 kDa), 
D1 (49 kDa), D2 (50 kDa), TH (60 kDa), DAT (69 kDa), ERα (66 kDa), Akt (56 kDa), 
phosphorylated s473-AKT (60 kDa), GSK3β (46 kDa), phosphorylated s9- GSK3β (46 kDa), 
PKCι/λ (68 kDa), PKM (55 kDa), COX-2 (72 kDa), DP1 (46 kDa), DP2 (~64 kDA), and κOR 
(~58 kDa).  Every gel contained 3-4 lanes loaded with the same control sample, (all brain 
samples, ABS). ABS were used to standardize protein signals between gels. Gels were 
transferred to nitrocellulose membranes in IBlot® Dry Blotting System (Life Technologies; 
Carlsbad, CA) for 9 minutes. Nitrocellulose membranes were then incubated in blocking solution 
containing 5% sucrose in Tris Buffered Saline with Tween-20 (TBST; 0.1% Tween-20 in TBS) 
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for 30 minutes at room temperature. Samples were incubated with the following primary 
antibodies for 18-36hrs: gapDH (1:2000; Abcam Inc., Cambridge, MA, USA), D1 (1:2000; 
Abcam Inc., Cambridge, MA, USA), D2 (1:2000; Abcam Inc., Cambridge, MA, USA), TH 
(1:2000; EMD Millipore Corp., Billerica, MA, USA), DAT (1:2000;  EMD Millipore Corp., 
Billerica, MA, USA), ERα (1:2000; Santa Cruz Biotechnology, Santa Cruz, CA), Akt (1:2000;  
Cell Signaling Technology, Danvers, MA, USA), phosphorylated s473-AKT (1:2000;  Cell 
Signaling Technology, Danvers, MA, USA), GSK3β (1:2000;  Cell Signaling Technology, 
Danvers, MA, USA), phosphorylated s9- GSK3β (1:2000;  Cell Signaling Technology, Danvers, 
MA, USA), PKM/ PKCι/λ (1:2000; Santa Cruz Biotechnology, Santa Cruz, CA), COX-2 
(1:2000; Santa Cruz Biotechnology, Santa Cruz, CA), DP1 (1:500; Cayman Chemical, Ann 
Arbor, Michigan, USA), DP2 (1:2000; ThermoFisher Scientific, Waltham, MA, USA ), and κOR 
1:2000; Abcam Inc., Cambridge, MA, USA). Membranes were washed in TBST for 20 min and 
probed with Horseradish Peroxidase (HRP) conjugated secondary antibody.  Membranes were 
incubated with Enhanced Chemiluminescence (ECL) substrate and exposed on CL-XPosure Film 
(Thermo Scientific; Rockford, IL).  GapDH was used as a control to standardize for protein 
concentration loaded on gels. Films were scanned for quantification with NIH Image J.    
 
4.3.11 Statistical analyses  
 
For behavioral and molecular analyses, a 1-way ANOVA across treatment groups 2-way 
ANOVA (sex x drug treatment) were used (Prism GraphPad 6.0 Statistical Package, La Jolla, 
California). Post-hoc analyses used controlled comparisons Bonferroni-corrected t tests.  
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4.4 Results 
 
4.4.1 Behavioral Shaping 
 
Analyses of RAM baseline and post-VOMA performance revealed one female mouse as an 
outlier from the rest of the group (z-scores 1.6 SDs and 1.5 SDs, respectively) and thus is not 
included for subsequent behavioral or molecular assays; total female control n=5. A timeline is 
provided to depict the duration of and the description for each phase of in-vivo assessments, to 
include RAM assessments and VOMA [Fig18A].  
 
4.4.2 Voluntary Ensure Consumption 
 
Across 28d of VOMA, n=6 male and n=5 female mice underwent control exposure to the 
Ensure, vehicle. For the first 3 days, mice were exposed to a total of 1 Ensure bait per day. For 
the next 3 days, mice were exposed to a total of 4 baits per day at 1 bait every 15min. From Day 
7 onward, control mice received 16 Ensure baits per day at 1 bait every 15min. Over the course 
of the 28d VOMA, control mice ate all Ensure baits. There were no differences in Ensure 
consumption between control male and control female mice [Fig 18B]. 
 
4.4.3 Voluntary Oral Methamphetamine Consumption 
 
Having placed n=14 mice per sex on VOMA (total n=28) [Fig18C], we observed that 
approximately 2/3 [n=9 mice per sex] of mice fell into a consistent and equivalent administration 
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rate, and that the remaining 1/3 of mice consumed significantly different (higher and lower vs the 
average consumer). A two-way repeated measures ANOVA of MA consumption between Low 
male VOMA consumers [n=5; 2.611 mg/kg/day over 28d +/-0.39 SEM] and medium male 
VOMA consumers [5.811 mg/kg/day over 28d +/-0.59 SEM] over 28d of VOMA showed a 
significant overall effect of consumption rate [F1,12=15.46, p<0.01]. A two-way repeated 
measures ANOVA of MA consumption between Low female VOMA consumers [n=2; 1.283 
mg/kg/day over 28d +/-0.15 SEM] and medium female VOMA consumers [6.01 mg/kg/day over 
28d +/-0.62 SEM] over 28d of VOMA showed a significant overall effect of consumption rate 
[F1,9=17.41, p<0.01]. A two-way repeated measures ANOVA between High female [n=3; 8.4 
mg/kg/day over 28d +/-0.91 SEM] and average female consumers [see above for statistics] over 
28d of VOMA showed a significant overall effect of consumption rate [F1,10=5.719, p<0.05]. To 
compare equivalent rates of voluntary MA consumption between sexes, our study focuses on the 
behavioral and molecular results from the 2/3 of mice that displayed this average (medium) 
consumption rate across males and females.  
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Figure 17. Escalation VOMA model produces equivalent, sustained MA consumption in 
both male and female mice. The study lasted 8 weeks, with acclimation and shaping during 
weeks 1-2; VOMA during weeks 3-6; behavioral analyses during weeks 7-8 (A). Control mice 
expose to vehicle (Ensure) only, consumed all baits delivered over 28 days of the VOMA study 
design (B). Escalation VOMA produces equivalent consumption of MA across medium male 
(average 5.8mg/kg MA/day over 28d) and medium female mice (average 6.0 mg/kg MA/day 
over 28d) (C). A Two-way ANOVA within-subjects analysis revealed an overall interaction 
effect of sex and day but no significant post-hoc effects on any given day. From a cohort of 28 
mice (n=14 from each sex) enrolled into VOMA, n=9 mice of each sex fell into the medium 
consumption group, while n=5 of each sex fell into high and/or low consumption groups. Body 
weight were tracked across all study weeks and a mixed model ANOVA revealed only overall 
sex and week differences between group body weights (D).  
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Following the escalation phase of VOMA, our analyses show that medium male mice consume 
an average of 7.68mg/kg MA/day (+/- 0.31 SEM) and medium female mice consume an average 
8.2mg/kg MA/day (+/-0.12 SEM) over the last 18d of VOMA; 5.8mg/kg/day MA (+/-0.59 SEM) 
and 6.0mg/kg MA/day (+/- 0.62 SEM) over 28d for medium male and medium female mice, 
respectively. When analyzing daily MA consumption between average male and average female 
mice over the 28d VOMA regimen (Figure 18C), a two-way repeated measures ANOVA shows 
no significant overall effect between sexes (F1,16=0.08, p=0.782), but both show a significant 
overall effect of day (F27,432=56.6, p<0.001) and a significant overall interaction effect of sex and 
day (F27,432=1.82, p<0.01). Upon closer analysis of the last 18d of VOMA, there was no 
significant overall effect between sexes (F1, 16=0.25, p=0.62) but a significant effect of day 
(F17,272=4.569, p<0.001) and a significant interaction effect of sex and day (F17,272=2.12, p<0.01). 
There were no post-hoc effects between groups.  
 
4.4.4 Body weights 
 
Body weights were tracked daily for all groups across all 8 weeks of the study [Fig 18D]. A 
repeated measures multivariate ANOVA of body weights across weeks revealed a significant 
overall effect of time (F7,27=133.1, p<0.001), a significant overall effect of sex (F1,33=150.1, 
p<0.001), no overall effect of MA (F1,33=0.697, p>0.5), no overall effect of MA dose by sex 
(F1,33=0.106, p>0.5), and a significant overall interaction effect of time by MA dose 
(F14,56=1.886, p=0.048) and a significant overall interaction of time by sex (F7,27=4.089, 
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p<0.01). These results indicate that within the study, body weights were affected more so in 
relation to time and were different between sexes. There is no strong indication that MA 
exposure affected the body weights of mice at any given point in the study. The overall 
interaction of time by MA dose is likely due to the lower body weights of High Female VOMA 
mice.  
 
4.4.5 Tail suspension and Elevated Plus Maze Assessments 
 
Possible effects of VOMA on depression were assessed by the tail suspension test. A two-way 
ANOVA of time spent immobile during the tail suspension test [Fig19A], across sex and drug 
treatment, revealed no significant overall effect of sex (F1,25=2.67, p>0.1), no significant overall 
effect of drug (F1,25=0.7, p>0.4), and no significant overall interaction effect of sex by drug 
(F1,25=0.6, p>0.4). This result indicates that Escalation VOMA had no effect on eliciting 
depressive phenotypes in these mice. Effects of VOMA on locomotion and anxiety were 
examined on the EPM. A two-way ANOVA of closed-arm entries [Fig 19B] on the EPM 
revealed a significant overall effect of sex (F1,25=5.67, p<0.05), no significant overall effect of 
drug (F1,25=0.039, p>0.8), and no significant overall interaction effect of sex by drug 
(F1,25=0.5, p>0.4). Post-hoc analyses revealed a significant difference between male and female 
VOMA mice (t25=2.53, p<0.05). A two-way ANOVA of open-arm entries on the EPM [Fig 
19C] revealed no significant overall effect of sex (F1,25=1.35, p>0.2), a significant overall effect 
of drug (F1,25=5.96, p<0.05) and no significant overall interaction effect of sex by drug 
(F1,25=0.006, p>0.9). These results show that VOMA increased exploratory and ambulatory 
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behavior in females (increased closed arm entries) while both sexes exhibited less anxiety 
following VOMA (increased open arm entries).  
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Figure 18. Escalation VOMA increases ambulatory behavior on the elevated plus maze.  
Following VOMA, mice underwent the tail-suspension test and results revealed no effect of drug 
or sex on immobility in this assessment, indicating that VOMA does not produce a depressive 
phenotype in either sex (A). Analysis of elevated plus maze activity shows female VOMA mice 
were more ambulatory as seen in their number of entries into closed arms (B) and in analyzing 
the entries into open arms, VOMA mice had significantly more than control mice (C). (*p<.05)  
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4.4.6 Working Memory Assessment 
 
Working-memory performance on the radial arm maze was analyzed across bait pairs, i.e. arms 
visited to collect the first set of baits (baits 1-2), second set baits (baits 3-4), third set of baits 
(baits 5-6) and fourth set of baits (baits 7-8). Within each bait-pair trial, the number of correct 
arms (always n=2) was divided by the total number of arms visited to collect the bait pair. A 
repeated measures three-way ANOVA of RAM performance between treatments (medium 
VOMA and control), sexes and across all bait pairs revealed an overall effect of bait pair 
(F3,75=106.4, p<0.001), no overall effect of treatment (F1,25=0.2018, p>0.6), no overall effect 
of sex (F1,25=0.32, p>0.5), no overall interaction effect of bait pair and sex (F3,75=2,12, p>0.1) 
a marginal overall interaction effect of bait pair and treatment (F3,75=2.65, p=0.055), no overall 
interaction effect of treatment and sex (F1,25=1.53, p>0.2) and no overall interaction effect of 
sex, treatment and bait pair (F3,75=0.6, p>0.6).  To more closely examine group comparisons, 
two-way ANOVAS were run to compare RAM performance across sex and treatments. A 
repeated measures two-way ANOVA of VOMA mice performance [Fig 20A] for each bait pair 
revealed no significant overall effect of sex (F1,16=1.75, p>0.2), a significant overall effect of 
bait-pair (F3,48=90.55, p<0.001) and a significant overall interaction effect of sex by bait 
(F3,48=3.48, p<0.05). Post-hoc analyses revealed a significant effect of sex between VOMA 
mice on bait-pair 5-6 (t64=2.94, p<0.05). A repeated measures two-way ANOVA of the 
performance of Control mice [Fig 20B] within each bait pair revealed no significant overall 
effect of sex (F1,9=0.31, p>0.5), a significant overall effect of bait-pair (F3,27=32.3, p<0.001) 
and no significant overall interaction effect of sex by bait (F3,27=0.35, p>0.79). Post hoc 
analyses revealed no significant differences between groups on any given bait trial. However, in 
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VOMA mice there was  a significant difference between sexes midway during the assessment 
when the working memory load is heavy (bait pair 5-6) with females showing poorer 
performance than males.  In addition, female mice exhibited a significantly greater number of 
working-memory errors committed during the RAM assessment, as a percent of controls, 
compared to males (t16=2.49, p<0.05) [Fig 20C]. These results highlight that Escalation VOMA 
affects working memory in females but not males.    
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Figure 19. Radial Arm Maze working memory assessments.  The 8-arm radial arm maze 
working memory assessment was used to test the short-term memory capacities of mice 
following VOMA. VOMA produced sex differences in performance of baits 5-6 (of total 8), with 
male mice performing better than female mice (A). Control treatment showed no significant sex 
differences in performance throughout the assessment (B). Female VOMA mice exhibit 
increased percent working-memory errors compared to male VOMA mice (C). (*p<.05)    
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4.4.7 Dopamine signaling markers 
 
Whole hippocampi were processed for western blot analyses. Cytosolic and synaptic fractions 
were processed for dopamine marker expression, as MA is known to preferentially affect 
monoaminergic pathways like the dopamine system 45. All values were corrected for gapDH. A 
two-way ANOVA of synaptic DAT [Fig 21A] revealed no significant effect of sex (F1,14=3.6, 
p>0.05), or drug (F1,14=1.17, p>0.2), but a significant interaction effect of sex by drug 
(F1,14=6.19, p<0.05). Post-hoc analyses revealed significant differences between male control 
mice and male VOMA mice (t14=2.65 p<0.05) and between male and female control mice 
(t14=2.97, p<0.05). A two-way ANOVA of cytosolic TH [Fig 21B] revealed a significant effect 
of sex (F1,21=18.68, p<0.001), no significant effect of drug (F1,21=0.14, p>0.7), or interaction 
effect of sex and drug (F1,21=0.056, p>0.8). Post-hoc analyses revealed significant differences 
between male and female mice in control (t21=2.96 p<0.05) and VOMA (t21=3.2 p<0.01) 
treatments. A two-way ANOVA of synaptic D1 [Fig 21C] revealed a significant effect of sex 
(F1,23=11.66, p<0.01), a significant effect of drug (F1,23=11.77, p<0.01), and a significant 
interaction effect of sex and drug (F1,23=9.14, p<0.01). Post-hoc analyses revealed significant 
differences between male VOMA mice and male control mice (t23=4.1 p<0.001) and male 
VOMA mice and female VOMA mice (t23=5.8 p<0.001). A two-way ANOVA of synaptic D2 
[Fig21D] revealed no significant effect of sex (F1,14=1.399, p>0.2), or drug (F1,14=0.1045, 
p>0.7), and a significant interaction effect of sex and drug (F1,14=8.051, p<0.05). Post-hoc 
analyses revealed a significant difference between male VOMA and male control mice (t14=2.9 
p<0.05). 
  
  112 
 
 
Figure 20. Escalation VOMA produces sex differences in hippocampal D1, D2 and DAT 
expression levels. Male and female mice exhibit different basal levels of hippocampal DAT and 
escalation VOMA decreases levels in males but not females (A). Male mice show higher levels 
of TH across control and VOMA conditions compared to females (B). Escalation VOMA 
increases hippocampal D1 levels in male mice but not in female mice (C). Escalation VOMA 
decreases hippocampal D2 levels in male mice but not in female mice (D). (*p<.05; **p<.01)  
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4.4.8 ERα and Akt/GSK3β signaling pathways 
 
Hippocampal cytosolic and synaptic fractions were analyzed for neuroprotective signaling 
pathways and estrogen receptor alpha (ERα) to examine the role of hormonal fluctuations on 
VOMA-induced neurochemical changes. All values were corrected for gapDH. A two-way 
ANOVA of synaptic ERα [Fig 22A] revealed no significant effect of sex (F1,19=1.528, p>0.2), a 
significant effect of drug (F1,19=4.97, p<0.05), and a significant interaction effect of sex and 
drug (F1,19=8.317, p<0.05). Post-hoc analyses revealed significant differences between male 
VOMA mice and male control mice (t19=2.57 p<0.01) and male VOMA mice and female 
VOMA mice (t19=3.48 p<0.01). A two-way ANOVA of cytosolic AKT [Fig 22B] between 
revealed no significant effect of sex (F1,19=0.086, p>0.7), a significant effect of drug 
(F1,19=4.692, p<0.05), and a significant interaction effect of sex and drug (F1,19=7.91, p<0.05). 
Post-hoc analyses revealed significant differences between male VOMA mice and female 
VOMA mice (t19=2.47 p<0.05) and female control mice and female VOMA mice (t19=3.5 
p<0.01). A two-way ANOVA of cytosolic phospho-AKT [Fig22C] revealed a significant effect 
of sex (F1,19=16.85, p<0.001), a significant effect of drug (F1,19=10.07, p<0.01), and no 
significant interaction effect of sex and drug (F1,19=0.2687, p>0.05). Post-hoc analyses revealed 
significant differences between male VOMA mice and female VOMA mice (t19=3.68 p<0.01) 
and female control mice and female VOMA mice (t19=2.59 p<0.05). A two-way ANOVA of 
synaptic GSK3β [Fig 22D] revealed a significant effect of sex (F1,19=21.95, p<0.001), no 
significant effect of drug (F1,19=0.065, p>0.8), or interaction effect of sex and drug 
(F1,19=1.81, p>0.1). Post-hoc analyses revealed significant differences between male VOMA 
mice and female VOMA mice (t19=4.81 p<0.001). A two-way ANOVA of synaptic phospho-
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GSK3 [Fig 22E] revealed a significant effect of sex (F1,19=6.841, p<0.05), no significant effect 
of drug (F1,19=1.904, p>0.1), or interaction effect of sex and drug (F1,19=0.175, p>0.6). Post-
hoc analyses revealed no significant differences between groups. A two-way ANOVA of 
synaptic phospho-GSK3β/GSK3β corrected ratios [Fig 22E] revealed no significant effect of sex 
(F1,20=1.159, p>0.2), a significant effect of drug (F1,20=4.956, p<0.05), and no significant 
interaction effect of sex and drug (F1,20=4.025, p>0.05). Post-hoc analyses revealed significant 
differences between male VOMA mice and female VOMA mice (t20=2.5 p<0.05) and between 
male VOMA mice and male control mice (t20=2.9 p<0.05). 
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Figure 21. Escalation VOMA produces sex differences in hippocampal ERα-GSK3β-
pathway activity. Male and female mice exhibit different levels of hippocampal ERα pathway 
activity following Escalation VOMA, with male mice showing increased expression of 
neuroprotective markers ERα (A), AKT (B), and pAKT (C) over female VOMA mice. AKT 
activation is known to directly mediate activation of GSK3β, whose phosphorylation is 
neuroprotective and dephosphorylated state is pro-apoptotic. Escalation-VOMA increases total 
GSK3β in females (D) but not males, dysregulates pGSK3β, and increases pGSK3β to total 
GSK3β ratios in males but not females, indicating that escalation produces sex-specific 
neuroprotection only in males. (*p<.05; **p<.01)  
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4.4.9 D-prostanoid receptor 1, 2 (DP1/DP2 receptor) 
Hippocampal cytosolic and synaptic fractions were analyzed for prostaglandin receptor 
expression, to examine the effects of VOMA on prostaglandin-mediated signaling. All values 
were corrected for gapDH. A two-way ANOVA of cytosolic COX-2 [Fig 23A] revealed a 
significant effect of sex (F1,21=4.569, p<0.05), a significant effect of drug (F1,21=5.422, 
p<0.05), and no significant interaction effect of sex and drug (F1,21=0.787, p>0.3). Post-hoc 
analyses revealed no significant differences between groups. A two-way ANOVA of synaptic 
DP1 [Fig23B] revealed a significant effect of sex (F1,17=11.01, p<0.01), no significant effect of 
drug (F1,17=0.288, p>0.5), or interaction effect of sex and drug (F1,17=3.09, p>0.05). Post-hoc 
analyses revealed a significant difference between male VOMA mice and female VOMA mice 
(t17=4.1 p<0.01). A two-way ANOVA of synaptic DP2 [Fig 23C] revealed no significant effect 
of sex (F1,22=1.159, p>0.2), drug (F1,22=2.92, p>0.5), or interaction effect of sex and drug 
(F1,22=2.386, p>0.05). Post-hoc analyses revealed a revealed no significant differences between 
groups. 
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Figure 22. Escalation VOMA produces sex differences in hippocampal DP1 but not COX-2 
or DP2 levels. In response to Escalation VOMA, Hippocampal COX-2 levels do not change 
significantly compared to controls (A). However, DP1 levels increase in female mice but not in 
male mice (B). Hippocampal DP2 levels do not show significant changes in male or female 
mice, with or without VOMA (C). (**p<.01)  
  118 
4.4.10 Hippocampal PKCι/λ and PKMζ 
Hippocampal cytosolic fractions were analyzed for atypical protein kinase c expression, PKMζ, 
known to play a major role in learning and memory 170, in order to examine the underlying 
mechanisms for VOMA induced memory deficits. All values were corrected for gapDH. A two-
way ANOVA of cytosolic PKCι/λ [Fig 24A] revealed no significant effect of sex (F1,22=0.209, 
p>0.6), drug (F1,22=0.014, p>0.9), or interaction effect of sex and drug (F1,22=0.532, p>0.4). A 
two-way ANOVA of cytosolic PKMζ [Fig 24B] revealed a significant effect of sex 
(F1,23=6.775, p<0.05), no significant effect of drug (F1,23=0.436, p>0.5), or interaction effect 
of sex and drug (F1,23=1.447, p>0.2). Post-hoc analyses revealed a significant difference 
between male VOMA mice and female VOMA mice (t23=2.98 p<0.05). 
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Figure 23. Escalation VOMA produces sex differences in hippocampal PKMζ. Escalation 
VOMA produces no differences in PKCι/λ across male or female mice (A). Escalation VOMA 
produces sex differences in hippocampal PKMζ levels, with females showing a significant 
reduction compared to males following VOMA (B). (*p<.05)  
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4.4.11 κ-Opioid receptor 
Hippocampal and NAc synaptic fractions were analyzed for κOR expression in order to 
characterize the molecular signaling underlying addiction as perpetuated by VOMA. All values 
were corrected for gapDH. A two-way ANOVA of hippocampal synaptic κOR [Fig 25A] 
revealed no significant effect of sex (F1,13=1.358, p>0.2), no significant effect of drug 
(F1,13=1.752, p>0.2), and a significant interaction effect of sex and drug (F1,13=12.32, p<0.01). 
Post-hoc analyses revealed significant differences between male control mice and female control 
mice (t13=3.06 p<0.05) and between male control mice and male VOMA mice (t13=3.74 
p<0.01). A two-way ANOVA of NAc synaptic D1 [Fig 25B] revealed a significant effect of sex 
(F1,17=40.69, p<0.001), no significant effect of drug (F1,17=4.23, p>0.05), or interaction effect 
of sex and drug (F1,17=0.9, p>0.3). Post-hoc analyses revealed significant differences between 
male control mice and female control mice (t17=3.32 p<0.01) and between male VOMA mice 
and female VOMA mice (t17=6.34 p<0.001). A two-way ANOVA of NAc synaptic κOR [Fig 
25C] revealed no significant effect of sex (F1,17=0.3478, p>0.5), no significant effect of drug 
(F1,17=0.026, p>0.8), and a significant interaction effect of sex and drug (F1,17=8.153, p<0.05). 
Post-hoc analyses revealed a significant difference between male VOMA mice and female 
VOMA mice (t17=2.98 p<0.05). 
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Figure 24. Escalation VOMA produces increased NAc κOR pathway activity. In response to 
Escalation VOMA, Hippocampal κOR levels are significantly decreased in male mice but not in 
female mice (A). Accumbal D1 levels are significantly decreases in female mice, with and 
without VOMA compared to males (B). Accumbal κOR levels are significantly increased in 
female mice after VOMA (C) indicating that differences in D1 signaling can be explained partly 
by κOR-dependent signaling that affects the dopamine system in this region. (*p<.05; **p<.01)  
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4.5 Discussion 
 
and females (6-8 weeks of age). Based on medium VOMA consumers [average 5.8-6mg/kg 
MA/day over 28d; 7.6-8.2 mg/kg/day over the last 18d] across males and females, we created 
cohorts that consumed equivalent amounts of MA during the 28d MA-treatment period.  Our 
results show sex-specific effects on behavior and neurochemical expression of various markers 
in the hippocampus. Behavioral results show that VOMA did not affect depression, was 
associated with increased anxiety in both sexes, and VOMA-females developed working-
memory deficits, but males did not. Analysis of dopamine markers show increased D1 in VOMA 
males compared to control males and VOMA females. There were no changes in DAT, TH or 
D2. Additionally, ERα increased in VOMA males including the downstream activation of pAkt 
and the ratio pGSK3β/GSK3β but not in females. These results indicate that VOMA males, but 
not females, have enhanced neuroprotection. In contrast, VOMA females show enhanced DP1 
and reduced DP2, a PGD2 receptor specific expression pattern reflecting heightened response to 
neuroinflammatory insults that is not observed in males. VOMA females also demonstrate 
enhanced -opioid receptor expression in the NAc indicative of negative symptomology 
associated with drug withdrawal but males did not. These results highlight the sex-specific 
vulnerability of chronic VOMA and the differential signaling pathways that are activated 
between sexes during adolescence and suggest a role of sex-specific treatments for addiction. 
 
4.5.1 Chronic VOMA impairs female working memory but not males  
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impulse control 25-27, 267. Many of these results are also shown in rodent studies 22, 268. MA-
induced working memory deficits in male mice show sustained effects for up to 7 weeks after a 
neurotoxic dose of MA and following 28d VOMA without escalation 189, 258. Our working 
memory assessment of adolescent mice shows working memory deficits in VOMA females as 
compared to control females, but such VOMA-induced deficits were not present in males. This 
effect is consistent with other reports identifying female enhanced sensitivity to MA 253-254, 269.  
However, following chronic or long-access to MA, both males and females show memory 
deficits but females exhibited higher MA intake and greater relapse to MA-seeking 253. Taken 
together, increased drug consumption combined with greater escalation demonstrates that 
females are more sensitive to the primary rewarding aspects of psychostimulant drugs which can 
disrupt reward driven memory tests 269. The superior performance of VOMA males compared to 
VOMA females may be the result of the MA-induced increase in D1 expression.  For example, 
increased striatal D1 has been shown to engender a readiness to respond to reward in animals 
pretreated with MA 270. Increased cortico-striatal D1 activity is predictive of reward-based 
learning 271, and increased sensitivity in this D1 pathway  can modulate working memory 
performance 272. Hippocampal-dependent working memory is also modulated by discrete 
changes in D1 activation 273. 
 
4.5.2 VOMA differentially affects Dopamine-related markers across sexes 
Our results show that VOMA did not alter TH, D2 or DAT expression in females, while males 
show decreases in DAT and D2 with increases in D1 compared to controls. This patterns 
suggests differential neurotoxic effects between sexes as  D2 and DAT are modulated by MA, 
and D2 antagonist have been shown to reduce neurotoxic effects of binge doses 118 as do DAT 
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inhibitors 274. Thus, lower levels of D2 and DAT could reflect neuroprotection in males. Previous 
studies have shown that escalating doses of MA offer some neuroprotection and/or slow the 
expression of neurotoxicity 19-20, 74. This interpretation is consistent with our previous VOMA 
study in males where we identified decreases in both TH and DAT following 28 VOMA without 
escalation 189. Our results with TH and DAT also indicate a sex-difference between control 
groups. This effect is in contrast to DAT levels reported in human studies showing higher DAT 
expression in females than males 275-277. Rodent studies have been less consistent, with some 
studies demonstrating greater DAT expression in females 278-280, and other showing no basal 
differences 281-283.  Additionally, some studies have shown that male DAT expression in striatum 
is more responsive to early life stress 284 and to high doses of MA 78. In striatum, DA 
concentration are not different between sexes however; males show great numbers of TH 
immunoreactive cells in the substantia nigra pars compacta compared to females 285-286. While no 
evaluation of TH or DAT across sexes has been done in the hippocampus, these current data 
indicate sex-specific expression differences in hippocampus for dopamine markers. 
 
VOMA also induced a significant increase in D1R expression in males but not females. Several 
reports show that MA-induced D1 activation is neuroprotective in the hippocampus by 
suppressing glutamatergic neurotransmission 130 and can reduce NMDA receptor mediated Ca2+ 
currents in hippocampal neurons, 131, in striatal neurons 127, and in producing inhibition on N-
type voltage-gated calcium channels 132.  In contrast, reports show that a D1R antagonist can 
reduce the neurotoxic effects of binge doses of MA 118. MA-induced D1R activation can also 
exacerbate glutamate toxicity 129. Therefore, it is possible that alterations in other receptors 
dictate whether increased D1R-levels are beneficial or detrimental. It is interesting that males 
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significantly upregulate D1R but females do not.  To date, we believe this is the first report 
identifying differential expression of MA-induced D1 across adolescent animals, suggesting that 
D1 could be a useful sex-specific therapeutic target for MA neurotoxicity.  
 
4.5.3 The role of dopamine induced expression on estrogen receptor α (ERα) 
 
Our results show males increase ERα following VOMA but females do not. Several reports have 
shown that estradiol can elevate ERα expression and have neuroprotective effects on MA 287-289 
and on mitigating MA-induced cognitive deficits 290. However, fewer studies have investigated 
the role of dopamine on estrogen receptors as we have here. While we do not know the 
mechanism explaining why this sex difference occurs, several reports show that ERs can also be 
activated in the absence of ligand. In vitro studies show that in the absence of estradiol, ERs are 
activated by several different neurochemical factors involving: EGF 291, IGF-I 292, caveolin-1 293, 
and activators of the protein kinase A and protein kinase C pathways 294 resulting in ER-
dependent gene transcription. Uterine EGF 295 and IGF-I 296 also result in ER-dependent gene 
transcription that can be blocked by an ER antagonist in vivo. Furthermore, ERs can be activated 
in vitro in the absence of estradiol by dopamine 297-299, and in vivo 300. Based on these studies, we 
suggest that the elevated expression of D1 in VOMA-treated males is presumably enhancing the 
ERα expression in a sex-specific manner.  
 
4.5.4 VOMA-induced sex differences in GSK3β and Akt signaling pathways associated with 
ERα 
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Estradiol and the IGF-1 receptor (IGF-1R) interact through ERα, allowing for the formation of a 
multimolecular complex composed by ERα, IGF-1R and components of this downstream 
signaling pathway such as, PI3K, Akt, and GSK3β 301-303. This ERα/IGF-1R interaction regulates 
PI3K-Akt-GSK3β-β-catenin signaling by estradiol 287, 302. It has been shown that inhibition of 
PI3K signaling abolishes the hippocampal neuroprotective actions of estradiol 304-305. In addition, 
the Akt activation by estradiol controls expression of the anti-apoptotic molecule Bcl-2 via the 
cAMP-response element-binding protein (CREB) 306-307. Downstream, Akt phosphorylates the 
glycogen synthase kinase 3β (GSK3β) and BAD proteins, thereby inhibiting their pro-apoptotic 
functions 303 inducing the activation of neuronal survival pathways 308. These studies are 
consistent with our results showing VOMA males increasing ERα together with sustaining 
higher levels of phosphorylated Akt and the pGSK3βGSK3β ratio and support a role for the 
neuroprotective effects of the GSK3β pathway as sexually dimorphic with chronic MA.  GSK3β 
is negatively regulated by the phosphorylation on its serine 9 (Cohen and Frame, 2001). In 
contrast, 40mg/kg IP MA following 7d abstinences produces greater neurotoxicity in males with 
decreased GSK3β and pAkt compared to females 78. This report suggests that at high doses of 
MA, females may have greater capacity for neuroprotection than males, while the opposite may 
be true for low or voluntary consumption rates of MA between sexes.   Nevertheless, our results 
show a sex-specific effect of GSK3β.  While no other reports have identified differences in 
expression levels of this marker, one report has identified differential activation of this signaling 
pathway mediated in leukemic stem cell therapy 309.  
 
4.5.5 Enhanced D-prostanoid receptor 1 (DP1 receptor) in females following VOMA  
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We evaluated the expression of both the DP1 and DP2 receptors following VOMA as an 
indicator of response to neuroinflammation 99. Prostaglandins initiate signaling through multiple 
receptors that have both proinflammatory and anti-inflammatory effects. Prostaglandin D2 
(PGD2), the most abundant prostaglandin in the brain 310, is considered anti-inflammatory when 
it signals through the D-prostanoid receptor 1 (DP1 receptor) present on myeloid cells but 
proinflammatory when it binds to the DP2/CRTH2 receptor on Th2 CD4 T cells 311-312. 
PGD2/DP1 signaling triggers G protein activation and cAMP production and has been associated 
with neuroprotection following diverse insults 99, 156, 313. In addition, a PGD2 derivative, 15d-
PGJ2, also signals through the DP1 receptor, inhibiting the inflammatory response 314. Inhibiting 
the DP1 receptor retards resolution of inflammation in macrophages 315. Conversely, the 
activation of DP2 receptor is associated with activation of proapoptotic signaling 316. Based on 
these reports, our data suggest that the differential expression observed in VOMA-females is a 
response to enhanced neuroinflammation, this data further suggests that males are not activating 
this signaling pathway for neuroprotection. CRTH2 signaling leads to GSK3β phosphorylation in 
TH2 lymphocytes, suggesting a role for this receptor in neuroprotection 317. However, the cell-
specific localization of this receptor could determine its protective or pro-inflammatory role as 
the activation of DP2/CRTH2 is associated with activation of proapoptotic signaling in 
cardiomyocytes 316. Based on these reports our data suggests that the differential expression of 
DP1 observed in VOMA-females is in response to enhanced neuroinflammation. The data 
further show that males are not activating this signaling pathway for neuroprotection. This 
hypothesis is consistent with our observations of increased neuroprotection via enhanced AKT-
pGSK3β found in males but not females. 
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4.5.6 VOMA induces sex-specific downregulation of PKMζ in the hippocampus 
Our analysis of sex-specific effects of VOMA include PKM  and PKCι/λ, synaptic plasticity 
markers associated with learning and memory 91, 318.  PKM is important for both late-phase LTP 
164 and long-term memory maintenance across various learning paradigms 88, 91, 165-166. PKM plays 
major roles in the trafficking of AMPA receptors that sustain LTP processes 168-169.  Our results 
show that PKM was significantly reduced in female VOMA mice compared to male VOMA mice 
and showed a trending decrease compared to controls. These results indicate that synaptic 
plasticity marker expression was differentially affected between sexes to produce the working 
memory deficit in female VOMA mice. Previously, it has been shown that PKCι/λ acts as a 
compensatory AMPAr trafficking enzyme in animal models where PKM was knocked-out, but 
in wildtype mice, PKM remains a pivotal enzyme regulating AMPAr trafficking, LTP, and 
memory 170. Still unknown is how PKCι/λ may undermine AMPAr trafficking and LTP deficits in 
models of stress and drug addiction, where PKM is consistently affected 89, 189, 258 The current 
study shows that PKCι/λ, unlike PKM, remains unchanged following VOMA in both male and 
female mice. This result suggests that following VOMA, PKCι/λ may act to partially rescue 
AMPAr and LTP deficits brought on by PKM. This hypothesis should be tested in future studies.  
 
4.5.7 Methamphetamine-induced modulation of κ-opioid receptor (κOR) and D1 in NAc 
We investigated -opioid receptor (κOR) expression in the NAc following VOMA as part of the 
ventral hippocampus-NAc circuit that participates in stimulant-induced expression of drug 
addiction behaviors 50  The reciprocal connections between the NAc and the hippocampus 
suggest that individual drug preferences could also influence the rewarding properties associated 
with spatial learning.  Our results show that VOMA females increase κOR in the NAc compared 
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to VOMA males. The expression of κOR in the NAc is associated with the negative affect of 
drug withdrawal and for the repeated, compulsive-like drug behavior 319-320. D1 activation 
regulates prodynorphin, the precursor of dynorphin, the endogenous ligand for κOR 321. ORs 
are located on striatal dopaminergic and glutamatergic terminals 322-323. Activation of dynorphin 
systems feedback to decrease dopamine release and contribute to the dysphoric syndrome 
associated with cocaine dependence 324-327, and long access to MA 319.  Consistent with our data, 
chronic MA leading to escalating consumption depends on the activation of the κOR system in 
the NAc shell 319. Selective inhibition of κOR blocks the development and/or expression of 
escalation of intravenous heroin intake 328, excessive alcohol self-administration 329 and MA self-
administration 319. Conversely, κOR agonists have been shown to induce dysphoric-like states in 
rodents and humans. This state in the ventral striatum may be driving escalation of intake via a 
negative reinforcement mechanism 319, 330. Our results suggest that females may have a 
vulnerability to dysphoric-mediated effects of κOR based on lower basal levels of D1 in the NAc 
compared to males. This hypothesis is consistent with 331 demonstrating that escalation of 
cocaine intake is driven by decreases in phasic dopamine release in the ventral striatum and that 
normalization of this state by the dopamine precursor l-DOPA can eliminate the escalation of 
cocaine intake. Thus, κOR acts as a presynaptic regulator of dopamine release, and, when the 
κOR system becomes sensitized by repeated psychostimulant use, it creates a state of deficient 
presynaptic dopamine release altering not only the rewarding properties of drugs, but also the 
food reward earned during spatial learning.  
 
4.6 Conclusion and Clinical Implications 
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To determine how chronic access to MA differentially affects the  hippocampus and NAc across 
adolescent male and female mice, we used a recently developed VOMA model 189. The findings 
show that with 10 days of escalating dosing, the males show reduced neurotoxic effects of MA 
compared to previously published results without escalation. Additionally, the VOMA females 
show exacerbated working memory deficits compared to VOMA males and show a distinctly 
different pattern of neurochemistry compared to males. Males increase D1, ERα pAkt, and 
pGSK3β /GSK3β ratio, suggesting neuroprotection, but females do not. Conversely, females 
show an increase in DP1 levels and a concomitant increase in κOR in NAc suggesting a response 
to increased neuroinflammation and elevated dysphoria that males do not. Presently little 
evidence exists to understand the differential drug seeking and vulnerabilities between sexes.  
Few studies have examined the long-term access drug seeking profiles in addition to their 
underlying mechanisms. The current work highlights differential activation of signaling 
pathways between males and females that have consumed voluntarily equivalent amounts of MA 
for 28d. The increased vulnerability of the 
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Figure 25. Escalation VOMA produces distinct behavioral and molecular responses 
between male and female mice. In response to Escalation VOMA, female mice exhibit 
compromised molecular signatures, including deficits in synaptic marker expression, increased 
neuroinflammatory activity, and decreased neuroprotective pathway activity that may underlie 
the cognitive deficits evidenced on the radial arm maze. Conversely, male mice that underwent 
Escalation VOMA exhibit increased neuroprotective activity, and no significant deficits in 
synaptic marker expression or neuroinflammatory activity, that result in no change in cognitive 
performance. This model has revealed a specific role for escalating methamphetamine doses to 
produce neuroprotection but only in male subjects. Female subjects are revealed to be susceptible 
to MA’s negative effects on cognition and the neurochemistry underlying behavioral 
performance.   
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CHAPTER 5: CONCLUSIONS 
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5.1 VOMA as a naturalistic model of Methamphetamine abuse 
 
The VOMA model has offered a new method to assess the voluntary consumption rates in a chronic 
MA exposure design. VOMA allows mice to titer the amount of drug administered in a given 
administration window, as reflected by the sustained level of MA consumed over several weeks. 
It is worth noting that within VOMA, mice do not consume all the MA baits delivered on any 
given day. As seen in our 28d and escalation models, on average, mice consume about half the 
total mg/kg MA made available. This indicates that although mice may want to consume MA via 
VOMA, this model does not produce mice that binge on MA, on any given day or throughout the 
administration period. Future studies should focus on the emotive, behavioral, and neural 
mechanisms that allow mice to self-regulate their MA consumption rates in VOMA. 
 
Furthermore, the VOMA models have proven useful in producing specific hippocampal-dependent 
cognitive impairments, as assessed by our RAM tasks. This behavioral deficits indicate that 
chronic MA abuse has the potential to affect this brain region, and further, that VOMA is useful 
in characterizing these effects where other models, such as self-administration, may have failed. 
In contrast to previous work on the cognitive effects of neurotoxic MA 1, VOMA more closely 
models natural MA consumption as it may occur in some populations. Specifically, I hypothesize 
that although VOMA may not be able to accurately depict the most addicted, highest consuming 
MA abusers, it can model the regular, chronic and moderate MA abusers. These populations may 
include frequent partiers, women seeking to dramatically lose weight and increase productivity, 
and even professionals looking to boost their day-to-day work output.  
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Our experiments have revealed that with VOMA, we can model preference for MA as seen in 
human populations. The use of forced MA administration in animal models has provided 
mechanistic understandings of the molecular and physiological effects that the drug has on the 
brain2. The current body of work has provided the next step in understanding the voluntary 
development of MA addiction. As my data shows, VOMA can produce a range in consumers (See 
Chapter 3). Intuitively, this result translates to our understanding of MA addiction in humans, as 
not all human MA consumers are considered highly dependent addicts332. Thus, the true range in 
human MA consumption likely follows a normal distribution, with very low and very high 
consumers at the ends of the population, with the majority of consumers falling in between these 
extremes. From my experiments, it seems very plausible that we have been able to mimic this 
hypothetical human distribution in mice. Through various experimental set-ups, we have produced 
low consumers, average consumers, and (not reported) the occasional super consumers. As 
mentioned above, more work is needed to understand the neural, emotive and/or behavioral 
mechanisms that produce this distribution in consumption rates. Preliminary work on this question 
has been shown in Chapter 3, where intracellular AKT-GSK3β and KOR activity has been 
measured and found to be dysregulated in female VOMA mice. Future experiments should be 
designed to target these pathways pharmacologically to assess output measure in behavior, DA 
toxicity, synaptic plasticity and neuroinflammation.   
 
Despite its reliance on oral-dosing, a route not considered to be wholly reflective of consumption 
by addicted individuals, VOMA is nonetheless a useful model that provides us with non-invasive 
and effective MA administration. Consistent deficits in RAM working memory, despite the design 
of VOMA experiments, indicate a loss of normal function in striatal-hippocampal signaling. This 
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is directly in line with decreases in dopamine marker expression in the hippocampus. These data 
show that VOMA is effective in producing the behavioral and molecular deficits produced by 
previous administration models. The critique against the oral route for this psychostimulant can be 
attributed to the notion that addicted individuals do not administer MA via this route, opting for 
intravenous or intranasal administration, as discusses above. However, data on human 
psychostimulant administration shows that oral administration makes a high percentage of abuse 
103, and that the half-life of MA via oral administration is not different from that of other routes 
101-102. Follow-up work on VOMA should aim to characterize the pharmacokinetics of MA 
following various dosing periods, such as after 1d VOMA, 7d VOMA, 14d VOMA and 28d 
VOMA at 1hr, 4hr, 8hr, and 24hr post final dose. Blood plasma and brain samples should be taken 
to assess for MA content and following VOMA for these periods of time. These follow-up 
experiments should help clarify the ability of VOMA to make MA available throughout the body 
and brain.  
 
5.2 Abstinence exacerbates the neuronal damage associated with Methamphetamine abuse 
 
MA is known to facilitate dopamine neuro-transmission45 which is the underlying molecular 
mechanism that produces euphoria and increases the risk for dependence and addiction333. As MA 
is used to increase DA release more and more during abuse, toxicity of DA terminals and/or 
compensatory signaling can lead to decreased baseline DA activity in the brain. In-vivo, this 
decreased DA pathway activity can lead to physiological dependence to MA334 as well as 
psychological and behavioral shifts that mirror neurological diseases like depression335 and 
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Parkinson’s disease336, among others. Thus, it seems that the time away from MA is as important 
to the progression of addiction and physiological changes that occur as a result of MA-abuse.  
 
Abstinence, whether permanent (as in our animal models) or transient (as can be seen in human 
addicts that cannot abstain), is an important factor to consider in understanding the behavior and 
physiological changes that result from MA abuse. To reiterate, MA acts on the dopamine system, 
and is predominantly acting to increase DA neurotransmission2. Although many of MA’s 
deleterious effects occur after this main molecular activity (including DA-quinone formation, DAT 
loss of function, etc.), special attention should be placed on the period of time following a period 
abuse. In humans, this period could be the time between last period of abuse and the one to come. 
In our VOMA model, this is the length of time following last dose and prior to tissue collection.  
 
Our findings are illuminating. Four (4) weeks of abstinence following VOMA or bolus-MA 
injections produces increased neurotoxic prostaglandin expression. This result is counter to what 
was expected, as MA alone should have increased chronic neuroinflammation. However, it was 
abstinence from the drug that produced this effect.  The mechanisms surrounding how exactly 
abstinence can increase the brain’s susceptibility to damage is unclear. Besides a need for more 
in-depth molecular analyses of the development of this diseased state of the brain following 
abstinence, molecular targets should be narrowed down to prevent neurodegenerative processes 
such as this from being initiated. One future experiment should include the use of DAT agonists 
(to increase the normal function of the molecule) and anti-inflammatories during or prior to 
VOMA, as my data has shown these two pathways to become dysregulated in the brain after 
abstinence. My hypothesis is that DAT loss of function (i.e. inverse agonism and depletion) could 
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perpetuate the effects of abstinence after MA abuse, but that either with DAT-agonists or anti-
inflammatories, we could prevent total DAT loss of function or prevent the downstream effects of 
increased DA availability in the synaptic cleft and then overall preventing a diseased state from 
developing in the brain. This is in line with the understanding that DAT regulates dopamine 
availability at synapses, and that dysregulation of this molecule disrupts dopamine-mediated 
signaling2. In the context of addiction, this MA-induced DAT loss of function could underlie the 
molecular mechanisms of MA physiological dependence.  
 
5.3 Escalating doses prevent the cognitive and neurochemical deficits associated with 
Methamphetamine abuse in male mice 
 
To our surprise, the escalation VOMA model (Chapter 4) was not able to produce the behavioral 
nor the neurochemical deficits in male adolescent mice produced in the static dose 28d VOMA 
model (Chapter 2), despite having similar total MA consumption over 28d (see Fig 27). As was 
discussed in Chapter 2, 28d VOMA using a static dose design produced spatial working memory 
and learning deficits in male mice. However, escalation VOMA did not produce greater cognitive 
deficits, or any at all. Upon analysis of hippocampal tissue samples, our neurochemistry results 
from escalation VOMA male mice aligned with the in-vivo work, revealing non-significant 
changes in tyrosine hydroxylase, no changes in neuroinflammation, and no changes in synaptic 
plasticity marker expression. This was in contrast to findings from the 28d static VOMA model, 
where DA toxicity, neuroinflammation, and synaptic plasticity marker expression was all affected.  
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Figure 26. Total MA consumed in 28d VOMA (Chapter 2) vs Escalation VOMA (Chapter 
3) in Male mice. There was no significant difference between the two groups.  
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The behavioral data suggest that although mice are consuming at high rates during VOMA, they 
have not yet reached stages of addiction that produce craving and depression. Thus, we can 
conclude that although VOMA may produce sensitization and high rates of voluntary 
consumption, the timeline or dose-design of this model is not sufficient to produce the latter stages 
of addiction associated with drug seeking, craving and dysfunction. Rather these data suggest that 
Escalation VOMA produces the early stages of MA abuse and addiction. Additionally, our model 
uses young adult mice (aged 8 weeks at start of VOMA), and our behavioral data could reflect a 
resilience in young mice to develop the behavioral deficits associated with MA exposure in older 
mice. More work needs to be done to compare how old and young mice respond to VOMA.  
 
This suggests that high rates of MA abuse may be maximally achieved through gradual 
introduction to the drug. Escalation better models how humans might initiate MA abuse, by 
gradual introduction to small doses of the drug. Our Escalation VOMA study has offered a more 
robust method to produce sustained MA consumption, as evidenced by the decreased variability 
in daily mg/kg MA consumed over the last 18d of the study. Additionally, this design is also able 
to produce Low consuming mice. Of 14 male mice that went into VOMA, 9 mice fell into our 
medium consumer group and 5 fell into the low consumer group. This distribution highlights the 
strength of this design to produce high numbers of mice that sustain higher levels of MA 
consumption. The data indicate a wider and clear split in consumption between groups and 
provides a means to analyze genetic and behavioral variability (and/or drift) that produces higher 
and lower consumers. 
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Taken together, these results suggest that escalating doses have some intrinsic neuroprotective 
qualities that protect the male brain and male behavior from a chronic MA’s detrimental effects. 
The nature and source of this neuroprotection is unclear, but previous work has shown that this 
phenomenon occurs in binge injection models, 19-20, associated with decreases in MA binding to 
DAT and DA release. However, the underlying mechanisms that produce this change in DA 
sensitivity remain unknown. This highlights the importance of MA’s action on DAT as a key factor 
in the neurotoxicity following MA. Finally, it is unknown how escalating oral MA provides 
protection or tolerance to MA challenges via DAT. This remains to be uncovered.  
 
Interestingly, escalation VOMA did re-capitulate decreases in DAT expression in the 
hippocampus, as seen in the 28d static VOMA model. DAT are modulated by MA and D2 
antagonist have been shown to reduce neurotoxic effects of binge doses 118 as do DAT inhibitors 
274. Thus, lower levels of DAT could reflect neuroprotection in males. Previous studies have shown 
that escalating doses of MA offer some neuroprotection and/or slow the expression of 
neurotoxicity 19-20, 74. This interpretation is consistent with the static 28d VOMA model where we 
identified decrease in both TH and DAT following 28 VOMA without escalation 189. Additionally, 
some studies have shown that male DAT expression in striatum is more responsive to early life 
stress 284 and to high doses of MA 78.  
 
5.4 Female mice are susceptible to the cognitive and neurochemical deficits associated with 
Methamphetamine abuse 
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Our Escalation VOMA model has revealed substantial sex differences in response to chronic MA 
exposure. Male mice exhibit neuroprotective profiles, both behavioral and molecular, following 
Escalation VOMA, but female mice show susceptibilities at these levels. Key neuroprotective 
pathways are compromised in female mice. 
 
Several reports show that MA-induced D1 activation is neuroprotective in the hippocampus by 
suppressing glutamatergic neurotransmission 130, by suppressing NLRP3 inflammasomes162 and 
by reducing NMDA receptor mediated Ca2+ currents in hippocampal neurons, 131 and in striatal 
neurons 127. Alternatively, others have shown that a D1R antagonist can reduce the neurotoxic 
effects of binge doses of MA 118 and that D1R activation following MA exposure can intensify 
glutamate toxicity 129. Thus, D1 alone cannot mediate neuroprotection or neuro-susceptibilities. 
Several reports have shown that estradiol can elevate ERα expression and have neuroprotective 
effects on MA 287-289 and on mitigating MA-induced cognitive deficits 290. The mechanisms 
underlying VOMA-induced upregulation of ERα in males is unknown and warrants further 
investigation, but previous work suggests that protein kinase A and protein kinase C pathways 294, 
as well as dopamine in vitro 297-299, and in vivo 300 can all increase ER levels. Thus, we hypothesize 
that females exhibit vulnerabilities to MA as result of a failure to increase D1-dependent signaling 
to parallel neuroprotective pathways. The underlying sex-differences in DA-mediated signaling in 
response to MA, including the receptors activated, should be delineated in future studies.  
 
The neuroprotective nature of ERα is derived from the signaling pathways that are initiated in 
response to its activity. Estradiol and the IGF-1 receptor (IGF-1R) interact through ERα, leading 
to a formation of a complex composed of ERα, IGF-1R and downstream signaling pathway 
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components such as, PI3K, Akt, and GSK3β 301-303. Akt activation by estradiol regulates expression 
of the anti-apoptotic molecule Bcl-2 via the cAMP-response element-binding protein (CREB) 306-
307. Downstream, Akt phosphorylates GSK3β and BAD proteins, which inhibits their pro-apoptotic 
functions 303 , leading to the activation of neuronal survival signaling308. Our data provide evidence 
that these neuroprotective pathways are only active in males exposed to escalation VOMA, to 
produce a behavioral and molecular phenotype unlike that seen in female mice (Fig 28).  GSK3β 
is negatively regulated by phosphorylation on its serine 9 site337. In contrast, 40mg/kg IP MA 
following 7d abstinences produces greater neurotoxicity in males with decreased GSK3β and pAkt 
compared to females 78. This report suggests that high doses of MA may produce greater 
neuroprotection for females than males, contrary to our escalating dose VOMA model. This 
highlights the utility of our model to elucidate the effects of naturalistic MA administration to 
investigate the underlying molecular mechanisms surrounding neurotoxicity and 
neurodegeneration. Overall, this indicates that more work is needed to characterize the role of 
GSK3β pathways in MA-induced toxicity, cognitive changes and addiction in males and females.  
 
To explore the sex differences in neuroinflammation following VOMA, we analyzed expression 
levels of DP1 and DP2 receptors, endogenous protein receptors to prostaglandin ligand activity99. 
Prostaglandin D2 (PGD2), the most abundant prostaglandin in the brain 310, and a deritive 15d-
PGJ2 314 are considered anti-inflammatory when it signals through the D-prostanoid receptor 1 
(DP1 receptor) present on myeloid cells but proinflammatory when it binds to the DP2/CRTH2 
receptor on Th2 CD4 T cells 311-312. PGD2/DP1 signaling triggers G protein activation and cAMP 
production and has been associated with neuroprotection following diverse insults 99, 156, 313. 
Inhibiting the DP1 receptor retards resolution of inflammation in macrophages 315. Conversely, the 
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activation of DP2 receptor is associated with activation of proapoptotic signaling 316. Our data 
suggests that the increased expression observed in VOMA-females was observed due to ongoing 
neuroinflammation, which is likely not as prevalent in male mice, if at all. CRTH2 signaling leads 
to GSK3β phosphorylation in TH2 lymphocytes, suggesting a role for this receptor in 
neuroprotection 317. However, the cell-specific localization of this receptor could determine its 
protective or pro-inflammatory role as the activation of DP2/CRTH2 is associated with activation 
of proapoptotic signaling in cardiomyocytes 316.  
 
We also assessed levels of PKMζ and PKCι/λ, synaptic plasticity markers associated with learning 
and memory 91, 318, of which PKMζ has been shown previously to be utilized differentially across 
sexes for spatial memory functions262. PKMζ was significantly reduced in female VOMA mice 
compared to male VOMA mice and showed a trending decrease compared to controls. PKCι/λ acts 
as a compensatory AMPAr trafficking enzyme in animal models where PKMζ was knocked-out, 
but in wildtype mice, PKMζ remains a pivotal enzyme regulating AMPAr trafficking, LTP, and 
memory 170. The current study shows that PKCι/λ, unlike PKMζ, remains unchanged following 
VOMA in both male and female mice. This result suggests that following VOMA, PKCι/λ may 
act to partially rescue AMPAr and LTP deficits brought on by PKMζ. These data reveal some of 
the molecular mechanisms that underlie the behavioral deficits exhibited by females in this VOMA 
model. The precise upstream mechanism that produce this result are unknown but could involve 
GSK3β-dependent activity, as it is known to regulate and be regulated by synaptic plasticity338-339 
and is known to regulate AMPA-receptor subunit trafficking340. Future studies should clarify the 
role of GSK3β in VOMA-induced cognitive and excitotoxic deficits. 
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Finally, our results show that VOMA females increase κOR in the NAc compared to VOMA 
males.  κOR expression in the NAc is associated with the negative effects of drug withdrawal and 
with repeated, compulsive-like drug behavior 319-320. Interestingly, κOR and D1 are linked, as 
activation of D1Rs regulates prodynorphin, the precursor of dynorphin, the endogenous ligand for 
κOR 321. κORs are located presynaptically on striatal dopaminergic and glutamatergic terminals 
322-323, acting to regulate/decrease neurotransmitter release. This action of κORs can contribute to 
the dysphoric syndrome associated with cocaine dependence 324-327, and long access to MA 319.  
This state in the ventral striatum may be driving escalation of intake via a negative reinforcement 
mechanism 319, 330, with increased κOR activity leading to increased dysphoria which leads to 
increased drug administration to counter this syndrome with stimulant-induced euphoria. This 
mechanism could explain sustained and/or escalating drug administration rates that underlie 
physiological dependence under a voluntary administration context. Our results suggest that 
females may have a vulnerability to dysphoric-mediated effects of κOR based on lower basal levels 
of D1 in the NAc compared to males, and increased κOR in the same brain region. Future studies 
should elucidate the role of κOR in the NAc to negatively couple effects of MA on cognition, as 
is seen in our study. Additionally, κOR antagonists should be used to clarify its role on female-
specific molecular vulnerabilities to dopaminergic signaling via D1. 
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Figure 27. Molecular Mechanisms of D1 and ERα- dependent neuroprotective signaling. In 
the context of methamphetamine, specific synaptic pathways initiate signaling to promote 
neuroprotection or neurotoxicity. Chapter 4 explores the contribution of these pathways in the 
context of neurochemical and behavioral effects in male and female adolescent mice.  
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CHAPTER 6: FUTURE DIRECTIONS 
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6.1 Delineating VOMA-induced deficits from abstinence-induced deficits 
The studies included into this dissertation have characterized the effects of VOMA following a 
14-day or 28-day drug administration period and abstinence periods. Data from Chapter 2 and 3 
indicate that our VOMA model can produce a neuroinflammatory response in the hippocampus, 
following 2 weeks or 4 weeks of abstinence. It is unclear if the neuroinflammation observed is 
due to MA neurotoxicity or abstinence. Additionally, it is unknown how mice will respond to 
longer administration periods lasting longer than 28 days. To delineate the onset and progression 
of VOMA-induced deficits apart from deficits induced by abstinence, I propose the following: 
1) A series of VOMA administration experiments to collect brain tissues at the end of 7, 28 and 
44 days of VOMA without any abstinence. 
a) This will characterize the onset and progression of neurochemical changes in the brain 
that occur as a result of progressively longer periods of VOMA. I hypothesize that 
neurotoxicity in tissues will positively correlate with length of VOMA, with increasing 
neuroinflammatory responses observed as the time spent in VOMA increases.  
b) Alternatively, mice on VOMA could show an unchanged neurochemical profile as a 
result of MA-induced D1 activity127, 130-132 and fail to exhibit robust molecular deficits 
throughout the course of the study. This finding could provide pivotal information about 
the utility of the VOMA model and overall, the long-term effects of voluntary oral MA 
on neurochemistry. A measure to assess the feasibility of this proposed experiment will 
be by tracking daily consumption. From the studies provided, we know that 
neuroinflammation is present in mice when consumption rates are sustained at or above 
~5mg/kg MA/day. In mouse populations consuming below this level, alternative 
approaches to answer this question should be used.  
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i) An alternative approach to delineate the neuroinflammatory response of VOMA apart 
from that of abstinence would be to expose mice to bolus injections of approx. 
5mg/kg MA/day and per the given study time-course above.  
c) Follow-up experiments should assess the cognitive performance of mice given 7 and 44 
days of VOMA. These experiments will provide a time-course for behavioral changes 
produced by progressively longer exposure to MA via VOMA. 
 
6.2 Mechanisms underlying abstinence-induced changes in behavior and neurochemistry 
following VOMA   
The studies included into this dissertation have utilized a 2-week (approximately 14 days) or 4-
week (approximately 28 days) abstinence period to carry out behavioral assessments and prior to 
specific tissue collections. Data from Chapter 3 suggests that abstinence can remediate cognitive 
deficits produced by MA, despite contradictory neurochemical changes that show activation of 
susceptible molecular signaling. It remains unclear what molecular signaling during abstinence 
can promote neurodegenerative or neuroprotective pathways in the brain. Thus, to clarify what 
molecular pathways should be targeted during abstinence in clinical settings, I propose the 
following: 
1) A series of VOMA administration experiments to assess efficacy of pharmacological agents 
administered during abstinence in preventing the neurochemical changes produced during a 
14-day, 28-day, and 44-day abstinence period 
a) A series of experiments using NSAIDs (targeting cyclooxygenases) and ERα agonist 
estradiol (starting administration right after VOMA) to test the efficacy of these 
pharmacological interventions in preventing the negative neurochemical changes 
associated with abstinence after MA exposure, such as decreases in DAT, increases in 
  149 
PGJ2 levels, COX-2, and others. Control groups will receive no additional treatment for 
44-days of abstinence.  
b) Follow-up experiments should assess the behavioral changes associated with 
administering these drugs during abstinence, with behavioral assessments occurring 
during and after the abstinence period 
c) Alternatively, we could observe that all neurodegenerative signaling could resolve by the 
end of 44 days of abstinence in control groups receiving no NSAID or estradiol 
treatment. This could suggest that no pharmacological intervention is necessary for 
resolution of these neurochemical deficits and that additional treatment only speeds up 
potential recovery of neurochemical deficits. In this scenario, follow-up experiments 
should the efficacy of NSAID or estradiol treatment in preventing deficits induced by a 
series of low-dose and high-dose challenge exposures of MA, following abstinence. This 
follow-up experiment will test the efficacy of pharmacological intervention in reducing 
the neurochemical deficits associated with a challenge exposure of MA, as previous 
studies have shown that neuroprotection by low-dose MA exposure is eliminated by 31 
days after low-dose MA exposure341. 
i) Alternative approaches should also be considered as per section 6.1.b above, if mice 
consume below 5mg/kg MA/day. Tissue analyses will be feasible from mice that 
receive similar doses in order to delineate the effects of compounding 
pharmacological interventions, as outlined above.  
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6.3 Mechanisms underlying neuroprotection or susceptibility following Escalation VOMA 
The last study in this dissertation showed that male mice exhibit protection from MA’s 
detrimental behavioral and neurochemical effects as a result of Escalating doses of MA. This 
effect was not seen in female mice. Further investigation at the molecular level showed that male 
mice showed significant increases in hippocampal estrogen receptor alpha, an effect that female 
mice did not show. These results warrant further investigation in order to determine more clearly 
the necessity of ERα-to-GSK3β activity to promote neuroprotection in males. To do so, I 
propose the following: 
1) A series of VOMA administration experiments with an added ERα antagonist manipulation 
in male mice to determine the necessity of ERα to promote behavioral and neurochemical 
resilience. An initial administration design could see the ERα antagonist delivered at the 
start, middle and end of the 28-day VOMA period. 
a) These experiments will determine if male mice need to upregulate ERα in order to show 
resilience to MA challenges. I hypothesize that male mice co-administered with an ERα 
antagonist will show behavioral and neurochemical deficits after VOMA 
i) Alternative approaches should also be considered as per section 6.1.b above, if mice 
consume below 5mg/kg MA/day. Tissue analyses will be feasible from mice that 
receive similar doses in order to delineate the effects of compounding 
pharmacological interventions, as outlined above.  
2) A series of VOMA administration experiments with an added ERα agonist manipulation in 
female mice to determine the necessity of ERα to promote behavioral and neurochemical 
resilience in these mice. An initial administration design could see the ERα agonist delivered 
at the start, middle and end of the 28-day VOMA period. 
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a) These experiments will determine if female mice that are given ERα agonist exhibit 
neuroprotection, like male mice have already shown 
i) Alternative approaches should also be considered as per section 6.1.b above, if mice 
consume below 5mg/kg MA/day. Tissue analyses will be feasible from mice that 
receive similar doses in order to delineate the effects of compounding 
pharmacological interventions, as outlined above.  
The potential pitfalls from these experimental designs include the unknown variable of the 10-
day escalation period of VOMA. This period, prior to the full-dose and access to MA, could 
prove to be a pivotal priming point for mice that enables activation or suppression of 
neuroprotective pathways. Thus, to answer this question, I propose the following: 
3) A series of Escalation-VOMA administration experiments to collect tissues at 2 days, 4 days, 
6 days, 8 days, and 10 days into the Escalation period. This design will enable us to capture 
the progression of neurochemical adaptation that mice are going through prior to engaging in 
full-access VOMA. 
a) These experiments will determine how male and female mice are responding to 
escalating doses of MA in the different tissues collected. It will be important to collect a 
few brain tissue and potentially a few relevant peripheral tissues (like liver, intestines, 
and others) to determine the full scope of molecular changes that mice exposed to 
escalation VOMA undergo.  
i) Alternative approaches should also be considered as per section 6.1.b above, if mice 
do not escalate as well as presented in Chapter 4. In this alternative experiment, 
injections of average daily escalating doses should be administered throughout the 
10-day escalation period to accomplish the tissue collection design above.  
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Appendix I. 5HT1b Mutant mice: MA consumption in VOMA 
 
 
Figure 28. 5-HT1b Knockout mice show different rates of consumption across sexes. Mice 
aged 8-16 weeks at the start of VOMA were put through Escalation VOMA. Tracking of MA 
consumption revealed the female KO mice consumed significantly less over the 28 days of 
VOMA [Two-way repeated measures ANOVA: across gender: F1,9=3.685, p=0.08; across days: 
F27,243=9.67, p<0.001; interaction of gender and days: F27,243=2.23, p<0.001]  
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Appendix II. Bolus MA increases chronic neuroinflammation after 6 weeks of abstinence 
 
Figure 29. Chronic neuroinflammation after 6 weeks of abstinence following bolus MA. 
Ubiquitin and COX-2 significantly increased 6 weeks after bolus (60mg/kg) MA treatment 
(*p<.05).  Ubiquitin and COX-2 quantified by WB. 
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